Base editors with improved precision and specificity
By combining CRISPR-Cas9 and uracil glycosylase inhibitors, using specific mutated cytidine deaminase, the problem of insufficient genome editing efficiency and accuracy in the prior art is solved, and high efficiency at specific sites is achieved. Accurate editing reduces the risk of off-target mutations and improves the potential for treating genetic diseases.
Patent Information
- Application Number
- CN201880048366.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2018-01-26
- Filing Date
- 2018-05-25
- Publication Date
- 2024-11-12
- Estimated Expiration
- 2038-05-25
AI Technical Summary
Existing base editing techniques are difficult to achieve efficient homologous mediated repair in the G2 and S phases of the cell cycle, and the repair efficiency of non-homologous terminal junction is low, which easily leads to competitive and uncontrollable mutations, limiting the Accuracy and safety of genome editing.
By binding the CRISPR-Cas9 system with uracil glycosylase inhibitor (UGI) and specific mutations of cytidine deaminase, limiting the activity of base editing at specific sites, using engineered deaminases such as APOBEC3A variants to Improve the specificity and accuracy of genome editing and reduce the occurrence of off-target mutations.
Efficient and precise genome editing without the need for donor DNA is achieved, reducing the risk of off-target mutations and improving the potential for the treatment of genetic diseases, especially under cell cycle-limiting conditions.
Smart Images

Figure CN110959040B_ABST
Abstract
Description
[0001] Priority declaration
[0002] This application claims the benefit of U.S. Provisional Patent Application Serial No. 62 / 511,296, filed May 25, 2017; U.S. Provisional Patent Application Serial No. 62 / 541,544, filed August 4, 2017; and U.S. Provisional Patent Application Serial No. 62 / 622,676, filed January 26, 2018. The entire contents of the foregoing are incorporated by reference.
[0003] Federally Sponsored Research or Development
[0004] This invention was made with U.S. Government support under Grant No. GM118158 awarded by the National Institutes of Health. The U.S. Government has certain rights in this invention. Technical Field
[0005] Described herein are methods and compositions for improving the genome-wide specificity of targeted base editing technologies. Background Art
[0006] Base editing (BE) technology uses an engineered DNA-binding domain (such as RNA-guided, catalytically inactive Cas9 (dead Cas9 or dCas9), nickase form of Cas9 (nCas9), or zinc finger (ZF) arrays) to recruit cytidine deaminase domains to specific locations in the genome to achieve site-specific cytosine→thymine conversion substitutions. 1,2 BE is a particularly attractive tool for treating genetic diseases manifested in cellular contexts where precise mutations generated by homology-directed repair (HDR) would be therapeutically beneficial but are difficult to generate by traditional nuclease-based genome editing technologies. Because the HDR pathway is restricted to the G2 and S phases of the cell cycle, for example, it is difficult or impossible to achieve HDR outcomes in tissues composed primarily of slowly dividing or post-mitotic cell populations. 3 In addition, the efficiency of HDR repair can be greatly reduced before and after editing due to competitive and more efficient induction of variable-length insertion / deletion mutations mediated by non-homologous end joining for the repair of nuclease-induced breaks. In contrast, BE technology has the potential to allow practitioners to generate highly controllable, highly precise mutations without the need for cell-type-variable DNA repair mechanisms. Summary of the invention
[0007] The CRISPR base editor platform (BE) possesses the unique ability to generate precise, user-defined genome editing events without the need for donor DNA molecules. The base editor (BE) efficiently induces cytidine to thymidine (C to T) base conversions in a site-specific manner as determined by the CRISPR guide RNA (gRNA) spacer sequence, wherein the base editor comprises a single-stranded nicking CRISPR-Cas9 (nCas9) protein fused to a cytidine deaminase domain and a uracil glycosylase inhibitor (UGI) (e.g., BE3) 1 . As with all genome editing agents, it is critical to first identify and then reduce the ability of BEs to generate off-target mutations prior to use in therapeutics, thereby limiting their potential to produce deleterious and irreversible gene-encoded side effects. Here, we present technical improvements to BE technology that will enable it to mature toward clinical significance. First, we describe methods to limit the absolute number of available cytosine substrates available for deamination by building BEs that utilize natural or engineered deaminases that can only deaminize cytosines present in a specific 2- or 3-nucleotide genomic context (Table 1).
[0008] These proteins may comprise one or more mutations listed in Table 7, for example, alone or in any possible combination for increasing the specificity of a deaminase protein or domain. These proteins may comprise one or more mutations listed in Table 8, for example, mutations intended to alter a targetable motif sequence, optionally in combination with any mutation in Table 7, for example, to produce engineered deaminase proteins or domains with altered and increased substrate sequences. Additionally, these proteins may comprise one or more mutations listed in Table 9, optionally in combination with any mutation listed in Table 7 or Table 8 to produce engineered deaminase proteins, for example, with specificity for changes in the first or third nucleotide in a trinucleotide motif and with increased specificity for its target motif relative to other possible deamination substrate motifs.
[0009] In some embodiments, the engineered variants of hAID, rAPOBEC1*, mAPOBEC3, hAPOBEC3A, hAPOBEC3B, hAPOBEC3C, hAPOBEC3F, hAPOBEC3G, or hAPOBEC3H comprise one or more mutations shown in Table 7, Table 8, and / or Table 9. In some embodiments, the mutations are N57A / G / Q / D / E; A71V; I96T; Y130F; or K60A / D / E or a combination thereof.
[0010] In some embodiments, the engineered variant of hAID, rAPOBEC1*, mAPOBEC3, hAPOBEC3A, hAPOBEC3B, hAPOBEC3C, hAPOBEC3F, hAPOBEC3G, or hAPOBEC3H comprises (i) one or more mutations shown in Table 7 and / or Table 8 and (ii) one or more mutations shown in Table 9.
[0011] In some embodiments, the engineered variant of hAID, rAPOBEC1*, mAPOBEC3, hAPOBEC3A, hAPOBEC3B, hAPOBEC3C, hAPOBEC3F, hAPOBEC3G, or hAPOBEC3H comprises hAPOBEC3A having a mutation at one or more of N57 (preferably N57G or N57Q); K60 (preferably K60A or K60D), and / or Y130 (preferably Y130F); or hAPOBEC3A having a mutation at one or more of hAID, rAPOBEC1*, mAPOBEC3, hAPOBEC3B, hAPOBEC3C, hAPOBEC3F, hAPOBEC3G or hAPOBEC3H having a mutation corresponding to N57 (e.g., at position 3 as shown in Table 7, e.g., G at position 3), K60 (e.g., at position 4 as shown in Table 7, e.g., D at position 4)), or Y130 (e.g., at position 6 as shown in Table 7, e.g., F at position 6).
[0012] In some embodiments, the engineered variant of hAID, rAPOBEC1*, mAPOBEC3, hAPOBEC3A, hAPOBEC3B, hAPOBEC3C, hAPOBEC3F, hAPOBEC3G, or hAPOBEC3H comprises hAPOBEC3A having mutations at N57 (preferably N57G) and Y130 (preferably Y130F); or hAID, rAPOBEC1*, mAPOBEC3, hAPOBEC3B, hAPOBEC3C, hAPOBEC3F, hAPOBEC3G, or hAPOBEC3H having a mutation corresponding to N57 (e.g., at position 3 as shown in Table 7, e.g., G at position 3) and a mutation corresponding to Y130 (e.g., at position 6 as shown in Table 7, e.g., F at position 6).
[0013] In some embodiments, the engineered variants of hAID, rAPOBEC1*, mAPOBEC3, hAPOBEC3A, hAPOBEC3B, hAPOBEC3C, hAPOBEC3F, hAPOBEC3G, or hAPOBEC3H comprise hAPOBEC3A with mutations at A71 and / or I96; or hAID, rAPOBEC1*, mAPOBEC3, hAPOBEC3B, hAPOBEC3C, hAPOBEC3F, hAPOBEC3G, or hAPOBEC3H with mutations corresponding to A71 and / or I96 (e.g., as shown in Table 10). For example, I96T, A71V, and Y130F each attenuate the editing activity of the deaminase from WT (which is critical due to off-target effects) without restoring much, if any, sequence preference, making them good candidates for all base editing sites.
[0014] In addition, provided herein is a method for treating a subject having a beta-thalassemia mutation HBB-28 (A>G), the method comprising delivering a therapeutically effective amount of a fusion protein according to any one of the preceding claims, wherein the deaminase comprises APO3A comprising a mutation at N57G or N57A or N57Q or K60A or K60D or Y130F, and preferably wherein the fusion protein comprises a ssDNA-nicking or catalytically inactive Cas9.
[0015] In some embodiments, the fusion protein is delivered in the form of RNP, mRNA, or plasmid.
[0016] In some embodiments, the methods comprise delivering the fusion protein ex vivo to a population of cells comprising CD34+ hematopoietic stem and / or progenitor cells collected from a subject under conditions sufficient to deaminize the mutant, and returning the cells to the subject.
[0017] Also provided herein are methods of deaminating selected cytidines in a nucleic acid, the methods comprising contacting the nucleic acid with a fusion protein or base editing system described herein.
[0018] Additionally, provided herein are compositions comprising a purified fusion protein or base editing system as described herein.
[0019] In addition, the present invention also provides nucleic acids encoding the fusion protein or base editing system described herein, as well as vectors containing the nucleic acids, and host cells containing the nucleic acids, such as stem cells, such as hematopoietic stem cells.
[0020] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those of ordinary skill in the art to which the invention belongs. Methods and materials used in the present invention are described herein; other suitable methods and materials known in the art may also be used. The materials, methods and examples are exemplary only and are not intended to be limiting. All publications, patent applications, patents, sequences and database entries and other references mentioned herein are incorporated by reference in their entirety. In the event of a conflict, the present specification (including definitions) will dominate.
[0021] Other features and advantages of the invention will be apparent from the following detailed description and drawings, and from the claims. BRIEF DESCRIPTION OF THE DRAWINGS
[0022] Figure 1 .Simplified diagram of an exemplary typical high-efficiency base editing system. A nicking Cas9 (nCas9) carrying a catalytically inactive mutation at one of its two nuclease domains binds to a target site determined by the variable spacer sequence of the sgRNA. The formation of a stable R-loop generates an ssDNA editing window on the non-deaminated strand. Cas9 generates single-strand breaks in genomic DNA, prompting the host cell to use the deaminated strand as a template to repair the damage, thus biasing the repair toward substitutions of cytosine→thymine conversions.
[0023] Figure 2A-2B . Figure 2A and Figure 2B The alignment of recognition loop 1 (RL1) and loop 7 are shown separately. Both regions show low conservation across the entire protein and have been empirically shown to contribute significantly to the sequence specificity of each enzyme or predicted to do so based on homology. The alignment was performed by the Blosum62 matrix and visualized in Geneious.
[0024] Figure 3A-3B Protein-DNA contacts formed between APO3A and the ssDNA substrate. RL1 residues are shown in magenta, loop 7 residues are shown in red, the ssDNA substrate is shown in yellow, and the remaining residues of APO3A are shown in grey. Figure 3A The orientation of all residues in RL1 and loop 7 for which we propose substitution mutations to alter or enhance the specificity of the deaminase domains described herein (SEQ ID NOs: 1-9) is shown. Figure 3B Base-specific hydrogen bonds formed between thymine at position -1 (relative to target C) and D131 are shown as black dashed lines (SEQ ID NOs: 10-18). PDB code: 5SWW.
[0025] Figure 4.APO3A-nCas9-UGI protein was overexpressed in U2OS cells along with a guide RNA targeting a site within the genomically integrated EGFP gene (SEQ ID NO: 19). After 72 hours, genomic DNA was extracted from these cells and subjected to Illumina sequencing. The C>T transition frequency of each cytosine nucleotide within the spacer was plotted for each of the 15 APO3A variants carrying single residue substitutions.
[0026] Figure 5 .APO3A-nCas9-UGI protein was overexpressed in U2OS cells along with a guide RNA targeting a site within the genomically integrated EGFP gene (SEQ ID NO: 19). After 72 hours, genomic DNA was extracted from these cells and subjected to Illumina sequencing. The C>T conversion frequency of each cytosine nucleotide within the spacer was mapped for APO3A-nCas9-UGI proteins carrying single residue substitutions at N57 or K60. Each of these proteins deaminated off-target GCT motifs within the editing window with reduced efficiency relative to the wild-type base editor protein, but retained effective deamination activity at on-target TCG motifs within the editing window.
[0027] Figure 6 The cytosine to thymine editing efficiency ratios of the on-target TCG motif and the off-target GCT motif (both within the editing window) at EGFP site 1 are plotted for each APO3A-nCas9-UGI protein carrying a single residue substitution. Proteins carrying N57 or K60 substitutions have increased specificity ratios relative to the wild-type APO3A base editor protein.
[0028] Figure 7 .APO3A-nCas9-UGI protein was overexpressed in U2OS cells along with a guide RNA targeting a site within the genomically integrated EGFP gene (SEQ ID NO: 20). After 72 hours, genomic DNA was extracted from these cells and subjected to Illumina sequencing. The C>T conversion frequency of each cytosine nucleotide within the spacer was plotted for each base editor protein.
[0029] Figure 8 Cumulative cytosine to thymine conversion frequencies of all cytosines within the editing window of the EGFP site 2 target (all of which are located within off-target trinucleotide motifs) are plotted for each base editor protein. APO3A base editor proteins carrying single residue substitutions at N57 and K60 have significantly reduced ability to deaminize off-target cytosines present in the editing window of this target site. Notably, APO3A N57A does not show any deaminase activity at this site.
[0030] Fig. 9 .U2OS cells carrying a stably integrated EGFP gene were transfected with a plasmid expressing a guide targeting EGFP (SEQ ID NO: 22) and the indicated base editor protein. After 72 hours, genomic DNA was extracted from the cells, the target site was amplified by PCR, and the PCR products were subjected to high-throughput Illumina sequencing. The C to T conversion frequency at homologous and non-homologous motifs was plotted for each transfection condition. The mutations made to hAPOBEC3A (APO3A) N57 were very effective in restoring the sequence specificity of the deaminase domain in the base editor structure.
[0031] Fig.10 HEK293T cells were transiently transfected with plasmids expressing the indicated gRNAs and base editor proteins. The APO3A BE3 protein carrying two substitutions generally lost significant activity at the homologous motifs in the two gRNAs tested. However, the APO3AN57Q / Y130F base editor 3 (BE3) double mutant retained activity towards the homologous motifs of both gRNAs while significantly reducing the efficiency of deamination at non-homologous motifs.
[0032] Fig.11 .HEK293T cells were transiently transfected with plasmids expressing the indicated gRNA and base editor proteins. After 72 hours, genomic DNA was extracted, the target site was amplified by PCR, and the PCR products were subjected to high-throughput Illumina sequencing. The C to T conversion frequency of all cytidines within the 20-nucleotide spacer sequence was plotted in a heat map format. Compared to BE3 and the engineered variants YE1, YE2, and YEE BE3 (YE BE3), all three APO3ABE3 proteins can strongly bias deamination toward homologous motifs, which reduces the frequency of such bystander mutations by incorporating point mutations into the rat APOBEC1 (rAPO1) deaminase domain that slow down its kinetic rate and limit its editing window length compared to BE3 44 Reference sequence, SEQ ID NOs: 23-28.
[0033] Fig.12 HEK293T cells were transiently transfected with plasmids expressing the indicated gRNAs and base editor proteins. After 72 hours, genomic DNA was extracted, target sites were amplified by PCR, and PCR products were subjected to high-throughput Illumina sequencing. The C to T conversion frequencies of all cytidines within a 20-nucleotide spacer sequence were plotted in a heat map format. All three APO3ABE3 proteins can strongly bias deamination towards cognate motifs compared to BE3 and YE BE3 proteins. Reference sequences, SEQ ID NOs: 29-34.
[0034] Fig.13 HEK293T cells were transiently transfected with plasmids expressing the indicated gRNAs and base editor proteins. Samples were processed as briefly described above. APO3A BE3 proteins carrying A71 or I96 mutations in addition to N57G greatly reduced deamination frequencies at non-homologous motifs. The ratio of homologous to non-homologous editing per site was plotted for all three sites for each of the variant base editor proteins, showing that APO3A N57G I96T BE3 achieved a homologous: non-homologous editing ratio of approximately 13 for each of the three sites tested. Reference sequences, SEQ ID NOs: 35-37.
[0035] Fig.14 HEK293T cells were transiently transfected with plasmids expressing the indicated gRNAs and base editor proteins. Samples were processed as briefly described above. To obtain the plotted deamination frequencies, all C to T conversion frequencies of cytidines that fell inside the editing window were summarized. APO3A BE3 induced very high levels of deamination at 16 of the 25 off-target sites. BE3 induced deamination at the same off-target sites as APO3A BE3, but at a lower frequency. APO3A N57G BE3 induced indels at only 6 of the 25 sites, and at a much lower frequency than BE3 at these 6 sites.
[0036] Fig.15 HEK293T cells were transiently transfected with plasmids expressing the indicated gRNAs and base editor proteins. Samples were processed as briefly described above. To obtain the plotted deamination frequencies, all C to T conversion frequencies of cytidines falling inside the editing window were summed. APO3A BE3 induced very high levels of deamination at 3 of the 15 off-target sites. BE3 induced deamination at the same off-target sites as APO3A BE3, but at a lower frequency. APO3A N57G BE3 did not induce deamination at any of the 15 off-target sites studied.
[0037] Fig.16 . Schematic diagram showing potential allelic products from targeting the HBB-28 (A>G) disease allele with a base editor protein. Mutation of the -25 bystander cytidine present in the mutation editing window causes a beta-thalassemia phenotype, independent of editing at the -28 position. Thus, it is critical that the -25 position is not edited by the base editor protein. SEQ ID NOs: 38-42 are shown.
[0038] Fig.17HEK293T cells carrying a chromosomally integrated 200 base pair fragment of the HBB-28 (A>G) pathogenic allele were transiently transfected with plasmids expressing HBB-28 targeting gRNA and the indicated BE proteins. BE3 and YE BE3 proteins deaminated cognate and noncognate cytidines at approximately equal frequencies, while APO3A N57G BE protein strongly deaminated the -28 homology motif to correct the disease while avoiding deamination of the second cytidine in the editing window. Reference sequence, SEQ ID NO: 43.
[0039] Fig.18 .BE3 and YE BE3 proteins induce deamination of the pathogenic HBB-28 (A>G) mutation, but this results in the generation of perfectly corrected alleles in less than 1% of the total alleles sequenced. In contrast, APO3A N57G BE protein generates perfectly corrected alleles in 15-22% of the total alleles sequenced.
[0040] Fig.19 HEK293T cells carrying a chromosomally integrated fragment of the HBB-28 (A>G) allele were transiently transfected with plasmids expressing the indicated gRNA and base editor proteins. Samples were processed as briefly described above. To obtain the plotted deamination frequencies, all C to T conversion frequencies of cytidines falling within the editing window were summarized. BE3 produced deaminations at 3 of the 8 off-target sites studied, while APO3A N57 BE3 produced deaminations at only one of the 8 sites and at a very low frequency. SEQ ID NO: 44 is shown. DETAILED DESCRIPTION
[0041] In the most potent BE configuration described to date, a cytidine deaminase (DA) domain and a uracil glycosylase inhibitor (UGI; a bacteriophage small protein that inhibits the host cell uracil DNA deglycosylase (UDG), the enzyme responsible for excision of uracil from the genome, are combined to form a cytidine deaminase (DA) domain. 1,4 ) are fused to nCas9 (derived from Streptococcus pyogenes Cas9 (SpCas9) or Staphylococcus aureus Cas9 (SaCas9)). nCas9 forms an R-loop at the target site defined by its single guide RNA (sgRNA) and adjacent protospacer adjacent motif (PAM) recognition, leaving approximately 4-8 nucleotides of non-target strand exposed as single-stranded DNA (ssDNA) near the PAM distal end of the R-loop ( Figure 1). This ssDNA region is a template that can be deaminated by the ssDNA-specific DA domain to generate guanosine: uracil (G: U) mismatches and defines the editing window. nCas9 nicks the non-deaminated strand of DNA and biases the conversion of G: U mismatches toward adenine: thymine (A: T) base pairs by instructing the cell to use the deaminated strand as a template to repair the nick lesion. To date, the DA domains described in these fusion proteins are rat APOBEC1 (rAPO1), activation-induced cytidine deaminase (AID) derived from lamprey (called CDA (PmCDA)), human AID (hAID), or a hyperactive form of hAID that lacks a nuclear export signal 1-2,5-7 BE technology is mainly established using SpCas9 protein targeting its nCas9 domain (nSpCas9), however although we mention nCas9 in this article, unless specifically indicated, any Cas9-like nickase can generally be used based on any ortholog of Cpf1 protein (including related Cpf1 enzymes).
[0042] An important consideration for using BE in a therapeutic setting will be to evaluate its genome-wide off-target mutagenesis capacity and to modify the technology to minimize or ideally eliminate the risk of stimulating deleterious off-target mutations. Using the current stage of BE technology, we can predict three potential sources of off-target mutation formation: (1) undesired modification of cytosine bases within the on-target site, as nCas9-stimulated R-loop formation can expose a total of eight on-target nucleotides to deamination; (2) off-target R-loop formation (Cas9 has a fully detectable ability to bind at off-target sites with varying degrees of homology to its sgRNA); 8-9 ) results in deamination of cytosine at these sites; and (3) BE-mediated deamination may occur at sites that are not bound to the DNA by the Cas9 portion of the fusion (e.g., activity mediated from solution or at sites that are only weakly specified by the deaminase itself). Here, we describe technical improvements to BE that can be used to reduce or eliminate potential unwanted BE mutagenesis.
[0043] Increasing the specificity of base editors by using cytidine deaminase domains with increased or altered target site preference
[0044] The current stage of BE technology uses the cytosine deamination activity of rat APOBEC1 (rAPOBEC1) to achieve cytosine → thymine conversion substitution in a window of about 8 nucleotides in single-stranded DNA (ssDNA). The ssDNA target window is formed by the R-loop generated by the nCas9 part of the BE fusion protein and starts about 4 nucleotides downstream of the 5'most nucleotide of the sgRNA complementary region. Therefore, the target C to be deaminated is within the gRNA target complementary sequence. Within the target sequence, it needs to be located at position 5, 6, 7, 8 or 9 counting from 5'.
[0045] The rAPOBEC1 domain itself has little inherent substrate sequence specificity and deaminates cytosines well in all sequence contexts, unless the base immediately 5' to the target C is a G, in which case deamination is less efficient, but still possible. Furthermore, when rAPOBEC1 is fused to nCas9, it appears to have processivity for multiple cytosines within the editing window. 1 - A single binding event at a ssDNA target window often results in the deamination of more than one cytosine in the window (if more than two cytosines are present).
[0046] Multiple deaminases per target window can lead to unwanted changes at the on-target binding site in the genome and at other off-target DNA sequences bound by nCas9. To some extent, the length and flexibility of the protein linker separating rAPOBEC1 and nCas9 can be varied to control unwanted deaminases inside the on-target editing window; however, this control cannot be fine-tuned to specific sequence positions in the editing window and still shows detectable deaminases outside the limited editing window. 10 .
[0047] To reduce or completely eliminate unfavorable deamination of non-target cytosines within the editing window of the on-target site, deamination of any cytosine at the off-target site, and limit unwanted processive deamination events at the on-target site, we established BE using engineered deaminase domains with inherent specificity for short sequence motifs and / or with non-processive deamination activity.
[0048] Base editors
[0049] In some embodiments, the base editor is a deaminase that modifies a cytidine DNA base, for example, a cytidine deaminase from the apolipoprotein B mRNA editing enzyme catalytic polypeptide-like (APOBEC) family of deaminase, including APOBEC1, APOBEC2, APOBEC3A, APOBEC3B, APOBEC3C, APOBEC3D / E, APOBEC3F, APOBEC3G, APOBEC3H, APOBEC4 (e.g., see Yang et al., J Genet Genomics. 2017 Sep 20; 44(9): 423-437); activation-induced cytidine deaminase (AID), for example, activation-induced cytidine deaminase (AICDA), cytosine deaminase 1 (CDA1) and CDA2, and cytosine deaminase acting on tRNA (CDAT). Table 1 below provides exemplary sequences; other sequences may also be used.
[0050] Table 1. Exemplary deaminases
[0051]
[0052] *From Saccharomyces cerevisiae S288C
[0053] Human AID (hAID), human APOBEC3, and mouse APOBEC3 enzymes (APO3A-hAPO3H, mAPO3) have specificity for one, two, or three additional nucleotides surrounding the target cytosine (Table 2) 11-16 . The specificity added from 1 to 3 additional nucleotides will result in a 4-fold to 64-fold reduction in the probability of non-target cytosines inside the BE editing window available for deamination in randomly distributed DNA. This will greatly enhance the specificity of the base editing enzymes at both on-target sites and nCas9 off-target sites with a high degree of similarity to the sgRNA within the genome and will also help limit potential, false sgRNA / nCas9-independent deaminases throughout the genome by greatly reducing the number of total substrate sites in the genome. Importantly, the inherent sequence specificity of the hAPO3 and mAPO3 enzymes increases the possibility that these proteins can be engineered to change or re-endow their target sequence specificity. In this case, many different 2- and 3-bp recognition deaminases can potentially be engineered to adapt to the sequence characteristics of each target substrate of interest.
[0054] Table 2. Cytidine deaminase domains described in this study and their substrate sequence preferences.
[0055] Variants Nucleotide sequence preference hAID 5'-WRC rAPOBEC1* 5'-TC≥CC≥AC>GC mAPOBEC3 5'-TYC hAPOBEC3A 5'-TCY hAPOBEC3B 5'-TCR>TCT hAPOBEC3C 5'-WYC hAPOBEC3F 5'-TTC hAPOBEC3G 5'-CCC hAPOBEC3H 5'-TTCA~TTCT~TTCG>ACCCA>TGCA
[0056] Nucleotide positions that were ambiguous or allowed more than 2 nucleotides were annotated according to the IUPAC code, where W=A or T, R=A or G and Y=C or T.
[0057] Each endogenous hAPO3 and mAPO3 enzyme has an inherent 2-3 nt target substrate motif preference at the site where it can act. For example, APO3A deaminates the bold cytosine in TC(A / G), while hAPO3G targets substrates of the form CCC. It would be advantageous to be able to adjust the range of sequence motifs that can be targeted by a given APO3 enzyme, thereby increasing the overall targeting range of this proposed class of substrate-specific APO3-containing BE agents. In addition, engineering the substrate specificity determining residues of the APO3 enzyme would allow us to not only change the preferred substrate site, but also improve the specificity of the APO3 enzyme for its preferred site relative to other closely matching di- or tri-nucleotide features that may be present in large quantities throughout the genome. The hAPO3 enzyme class recognizes its cognate sequence motif through direct contacts formed between residues in two recognition loops with variable sequence composition, called recognition loop 1 (RL1) and loop 7. 12-13,17-22 (See Table 3, Figure 2A-2B and Figure 3A-3B ). Other enzymes have the aforementioned substitution mutations made to these residues that relax or alter the specificity of these domains. For example, mutating hAPO3G loop 7 residues D316 and D317 to arginine changes the enzyme's substrate specificity from CCC to CCC (where the bold C indicates a substrate for deamination) 23 Mutating hAPO3F D311A increased targeting to both TGC and TCC, whereas the unmodified enzyme preferentially targeted TTC 15 In addition, chimeric APO3A proteins in which the RL1 residue had been replaced by the RL1 residue of hAPO3G significantly relaxed the specificity of the enzyme. 24 , and replacement of hAID loop 7 residues by those from hAPO3G or hAPO3F alters the target sequence characteristics of the mutant hAID enzyme to resemble those of the donor enzyme 25 This study established that substitution mutations to residues in RL1 and loop 7 are predicted to alter the specificity of the APO3 protein by altering the base-specific contacts formed between the protein and the target ssDNA, but there are no reports of reengineering APO3 substrate sequence specificity beyond these initial studies. Additionally, to our knowledge, no group has described a strategy to enhance the specificity of these domains for their target sequence motifs.
[0058] Table 3. Recognition loop residues
[0059] Deaminase Identification of loop 1 residues Loop 7 residues hAID V18-K22 A111-P123 rAPOBEC1* D11-R15 A117-R126 mAPOBEC3* L33-K37 S129-E138 hAPOBEC3A G25-R28 A127-L135 hAPOBEC3C L24-N28 A121-C130 hAPOBEC3G E209-R213 A312-R320 hAPOBEC3H* K16-Y23 S109-P118 hAPOBEC3F L207-Y211 A304-D313
[0060] Each of the recognition loop 1 and loop 7 regions represents an enzyme region known to contribute to the sequence specificity of the enzyme or, in the absence of structural information, predicted to contribute to the sequence specificity based on sequence alignments (see Figure 3A-3B ) (* indicates proteins for which sufficient structural information is lacking). All protein sequences were obtained from uniprot.org. All position information refers to positions within the full-length protein sequence as described below.
[0061] For this purpose, substitution mutations may be made to residues present in RL1 and / or loop 7 (see Table 3 for the corresponding residues for each APO3 or AID enzyme and see Table 3 for an alignment of these proteins). Figure 2A-2B ). In order to sample the maximum number of amino acid substitution combinations at positions in RL1 or loop 7, we will randomize the amino acids in these loops and use a bacterial selection protocol to select library members with robust deamination activity towards the desired sequence. In the case of loop 7, residues believed to be primarily responsible for specifying the sequence motif will be individually mutated to residues that can be expected to form base-specific interactions with the desired sequence motif, and the remaining positions in loop 7 will be randomized. For example, APO3A residue D131 is known to form a hydrogen bond with 5'-TCY (where the bold T represents a base-specific contact). In order to change the sequence specificity of APO3A from TCT>ACT, we first designed APO3A mutants carrying D131 to N, Q, or R substitutions. Each of these APO3A variants was then modified at positions 132-134 by cloning synthetic degenerate oligonucleotide libraries made using NNB, NNS, or NNK streamlined codon sets (where N=A / C / G / T, B=C / G / T, S=C / G and K=G / T).
[0062] The substitution mutations made to each of these residues include any of the 20 typical amino acids in any combination with the substitution mutations made to any other specified residue position. In addition, these mutations can be combined with truncating the enzymes in Table 3 to the minimum domain required for catalytic activity (catalytic domain; CD). For examples of CDs derived from subsets of enzymes described herein, see the exemplary protein sequences. These mutations can also be made in the presence or absence of all or any combination of the 5 previously displayed substitution mutations to increase the solubility and catalytic activity of hAPO3G (see Table 4 for a complete list of homologous substitution mutations for each APO or AID enzyme described herein). It is worth noting that the deaminase domains listed in Table 1 may have advantageous inherent properties relative to rAPOBEC1 lacking any engineering that we may make. Thus, in addition to any engineered variants that we can produce, we also describe the unmodified domains listed in Table 1 here.
[0063] Table 4. Exemplary substitution mutations
[0064] Deaminase Displacement 1 Displacement 2 Displacement 3 Displacement 4 Displacement 5 hAID - - F109K - - rAPOBEC1* L39K - Y115K - - mAPOBEC3* - - F127K - - hAPOBEC3A - - F125K - C171A hAPOBEC3G L234K C243A F310K C321A C356A hAPOBEC3H* - - F107K - - hAPOBEC3F - - F302K - -
[0065] Each substitution mutation represents a residue of the enzyme known to contribute to the stability and solubility of the enzyme, or in the absence of structural information, an enzyme residue predicted to contribute to sequence specificity based on sequence alignment with hAPOBEC3G (* indicates a protein lacking sufficient structural information). All position information refers to the wild-type protein sequence obtained from uniprot.org. The exact positions of these residues may vary in engineered variants such as hAIDv. All position information refers to positions within the full-length protein sequence as described below.
[0066] CRISPR-Cas nucleases
[0067] The sequence-specific deaminases described herein are fused to the Cas9 nickase. Although we refer to nCas9 herein, any Cas9-like nickase can generally be used based on any ortholog of the Cpf1 protein (including related Cpf1 enzymes) unless otherwise indicated. Table 5 provides an exemplary list.
[0068] Table 5. List of exemplary Cas9 orthologs
[0069]
[0070] These orthologs, mutants and variants thereof known in the art can be used in any fusion protein described herein. For example, see WO 2017 / 040348 (which describes SaCas9 and SpCas9 variants with increased specificity) and WO 2016 / 141224 (describing SaCas9 and SpCas9 variants with altered PAM specificity).
[0071] The Cas9 nuclease from Streptococcus pyogenes (hereafter referred to as Cas9) can be guided by simple base pair complementarity between an engineered guide RNA (gRNA), such as 17-20 nucleotides of a single guide RNA or a crRNA / tracrRNA pair, and a complementary strand of a target genomic DNA sequence of interest adjacent to a protospacer sequence adjacent motif (PAM), such as a PAM matching the sequence NGG or NAG (Shen et al., Cell Res (2013); Dicarlo et al., Nucleic Acids Res (2013); Jiang et al., Nat Biotechnol 31, 233-239 (2013); Jinek et al., Elife 2, e00471 (2013); Hwang et al., Nat Biotechnol 31, 227-229 (2013); Cong et al., Science 339, 819-823 (2013); Mali et al., Science 340, 819-823 (2013). 339, 823-826 (2013c); Cho et al., Nat Biotechnol 31, 230-232 (2013); Jinek et al., Science 337, 816-821 (2012)). Engineered CRISPR from Prevotella and Francisella 1 (Cpf1) nucleases can also be used, for example, as described in Zetsche et al., Cell 163, 759-771 (2015); Schunder et al., Int J Med Microbiol 303, 51-60 (2013); Makarova et al., Nat Rev Microbiol 13, 722-736 (2015); Fagerlund et al., Genome Biol 16, 251 (2015). Unlike SpCas9, Cpf1 requires only a single 42nt crRNA with 23nt nucleotides at the 3' end that are complementary to the protospacer sequence of the target DNA sequence (Zetsche et al., 2015). In addition, SpCas9 recognizes the NGG PAM sequence present in the 3' protospacer, while AsCpf1 and LbCp1 recognize the TTTN PAM present in the 5' protospacer (ibid.).
[0072] In some embodiments, the systems of the invention utilize wild-type or variant Cas9 proteins from Streptococcus pyogenes or Staphylococcus aureus or wild-type Cpf1 proteins from Acidaminococcus sp. BV3L6 or Lachnospiraceae bacterium ND2006, as encoded in bacteria or codon-optimized for expression in mammalian cells and / or modified in their PAM recognition specificity and / or their genome-wide specificity. A variety of variants have been described; see, for example, in particular WO2016 / 141224; PCT / US2016 / 049147; Kleinstiver et al., Nat Biotechnol. 2016 Aug; 34(8):869-74; Tsai and Joung, Nat Rev Genet. 2016 May; 17(5):300-12; Kleinstiver et al., Nature. 2016 Jan 28; 529(7587):490-5; Shmakov et al., Mol Cell. 2015 Nov 5; 60(3):385-97; Kleinstiver et al., Nat Biotechnol. 2015 Dec; 33(12):1293-1298; Dahlman et al., Nat Biotechnol. 2015 Nov;33(11):1159-61; Kleinstiver et al., Nature. 2015 Jul 23;523(7561):481-5; Wyvekens et al., Hum Gene Ther. 2015 Jul;26(7):425-31; Hwang et al., Methods Mol Biol. 2015;1311:317-34; Osborn et al., Hum Gene Ther. 2015 Feb;26(2):114-26; Konermann et al., Nature. 2015 Jan 29;517(7536):583-8; Fu et al., Methods Enzymol. 2014;546:21-45; and Tsai et al., Nat Biotechnol. 2014 Jun;32(6):569-76. The guide RNA is expressed or present in the cell together with Cas9 or Cpf1. One or both of the guide RNA or nuclease can be transiently or stably expressed in the cell or introduced as a purified protein or nucleic acid.
[0073] In some embodiments, Cas9 further comprises one of the following mutations, which reduces the nuclease activity of Cas9; for example, for SpCas9, a mutation at D10A or H840A (which produces a single-stranded nickase).
[0074] In some embodiments, the SpCas9 variant also comprises a mutation that abolishes the nuclease activity of Cas9 at one of the following amino acid positions: D10, E762, D839, H983, or D986 and H840 or N863, e.g., D10A / D10N and H840A / H840N / H840Y, so that the nuclease portion of the protein is catalytically inactive; substitutions at these positions can be alanine (as they are in Nishimasu et al., Cell 156, 935–949 (2014)) or other residues, e.g., glutamine, asparagine, tyrosine, serine, or aspartic acid, e.g., E762Q, H983N, H983Y, D986N, N863D, N863S, or N863H (see WO 2014 / 152432).
[0075] In some embodiments, Cas9 is fused to one or more uracil glycosylase inhibitor (UGI) sequences; exemplary UGI sequences are as follows:
[0076] TNLSDIIEKETGKQLVIQESILMLPEEVEEVIGNKPESDILVHTAYDESTDENVMLLTSDAPEYKPWALVIQDSNGENKIKML (SEQ ID NO: 45). The UGI may be N-terminal, C-terminal, or absent (and optionally expressed in cis, e.g., expressed in cis, or provided or administered, respectively).
[0077] How to use
[0078] The compositions and methods of the present invention can be used to enhance genome-wide specificity by engineered APO3A deaminases. For example, when delivered by plasmid transient transfection, APO3AN57G used in the BE3 structure has increased genome-wide specificity at off-target sites determined by the identity of the spacer sequence of the guide RNA. In addition, these methods can include, for example, using RNP or mRNA transfection to deliver APO3ABE3 having any mutation in Table 7 to limit genome-wide off-target mutation formation by base editor reagents. In addition, APO3ABE3 (either by itself or together) having any mutation in Table 7 can be delivered using plasmid transient transfection, RNP or mRNA, wherein the Cas9 (nCas9) that produces ssDNA nicks or is catalytically inactive is any engineered SpCas9 protein that recognizes a PAM sequence orthogonal to the SpCas9 NGG PAM to limit off-target mutagenesis caused by the fusion protein. 46In addition, APO3A with any mutation in Table 7 fused to S. aureus Cas9 or an engineered S. aureus Cas9 that recognizes an orthogonal PAM sequence may also be used. 47 .
[0079] Variants
[0080] In some embodiments, the components of the fusion protein are at least 80% identical to the amino acid sequence of an exemplary sequence (e.g., as provided herein), e.g., at least 85%, 90%, 95%, 97% or 99% identical, e.g., having differences at up to 5%, 10%, 15% or 20% of the residues of the exemplary sequence, e.g., substituted with conservative mutations other than the mutations described herein. In preferred embodiments, the variant retains the desired activity of the parent, e.g., nickase activity, and / or the ability to interact with a guide RNA and / or a target DNA.
[0081] To determine the percent identity of two nucleic acid sequences, the sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in one or both of the first and second amino acid or nucleic acid sequences for optimal alignment, or non-homologous sequences can be ignored for comparison purposes). The length of the reference sequence aligned for comparison purposes is at least 80%, and in some embodiments at least 90% or 100% of the length of the reference sequence. The nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position (as used herein, nucleic acid "identity" is equivalent to nucleic acid "homology"). The percent identity between the two sequences is a function of the number of identical positions shared by the sequences, taking into account the number of gaps and the length of each gap that need to be introduced for optimal alignment of the two sequences. The percent identity between two polypeptide or nucleic acid sequences can be determined in various ways within the skill in the art, for example, using publicly available computer software such as Smith Waterman Alignment (Smith, TF and MS Waterman (1981) J Mol Biol 147:195-7); incorporated into GeneMatcher Plus TM, Schwarz and Dayhof (1979) Atlas of Protein Sequence and Structure, Dayhof, MO ed., pp. 353-358, "BestFit" (Smith and Waterman, Advances in Applied Mathematics, 482-489 (1981)); BLAST program (Basic Local Alignment Search Tool; (Altschul, SF, W. Gish et al., (1990) J Mol Biol 215:403-10), BLAST-2, BLAST-P, BLAST-N, BLAST-X, WU-BLAST-2, ALIGN, ALIGN-2, CLUSTAL or Megalign (DNASTAR) software. In addition, those skilled in the art can determine suitable parameters for weighing the comparison, including any algorithm required for achieving maximum comparison over the full length of the compared sequences. Usually, for proteins or nucleic acids, the length of comparison can be any length, up to and including the full length (e.g., 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95% or 100%). For the purposes of the compositions and methods of the present invention, at least 80% of the full length of the sequences are compared.
[0082] For purposes of the present invention, sequence comparisons and percent identity between two sequences can be determined using the Blossum 62 scoring matrix with a gap penalty of 12, a gap extension penalty of 4, and a frameshift gap penalty of 5.
[0083] Conservative substitutions generally include substitutions within the following groups: glycine, alanine; valine, isoleucine, leucine; aspartic acid, glutamic acid, asparagine, glutamine; serine, threonine; lysine, arginine; and phenylalanine, tyrosine.
[0084] Also provided herein are isolated nucleic acids encoding split deaminase fusion proteins; vectors comprising isolated nucleic acids, the nucleic acids optionally being operably linked to one or more regulatory domains to express variant proteins; and host cells, e.g., mammalian host cells, comprising the nucleic acids and optionally expressing variant proteins. In some embodiments, the host cell is a stem cell, e.g., a hematopoietic stem cell.
[0085] The split deaminase fusion proteins described herein can be used to alter the genome of a cell. These methods generally include expressing or contacting a split deaminase fusion protein in a cell; in versions using one or two Cas9s, these methods include using a guide RNA having a region complementary to a selected portion of the cell genome. Methods for selectively altering the genome of a cell are known in the art, for example, see US 8,993,233; US 20140186958; US 9,023,649; WO / 2014 / 099744; WO 2014 / 089290; WO2014 / 144592; WO144288; WO2014 / 204578; WO2014 / 152432; WO2115 / 099850; US8,697,359; US201600245 29; US20160024524; US20160024523; US20160024510; US20160017366; US20160017301; US20150376652; US20150356239 ;US20150315576;US20150291965;US20150252358;US20150247150;US20150232883;US20150232882;US20150203872;U S20150191744; US20150184139; US20150176064; US20150167000; US20150166969; US20150159175; US20150159174; US20 150093473; US20150079681; US20150067922; US20150056629; US20150044772; US20150024500; US20150024499; US2015 0020223; US20140356867; US20140295557; US20140273235; US20140273226; US20140273037; US20140189896; US2014011 3376; US20140093941; US20130330778; US20130288251; US20120088676; US20110300538; US20110236530; US201102177 39; US20110002889; US20100076057; US20110189776; US20110223638; US20130130248; US20150050699; US20150071899;US20150050699; US20150045546; US20150031134; US20150024500; US20140377868; US20140357530; US20140349400; US20140335620; US20140335063; US20140315985; US20140310830; US20140310828; US20140309487; US20140304853; US20140298547; US20140295556; US20140294773; US20140287938; US20140273234; US20140273232; US20140273231; US20140273230; US20140271987; US20140256046; US20140248702; US20140242702; US20140242700; US20140242699; US20140242664; US20140234972; US20140227787; US20140212869; US20140201857; US20140199767; US20140189896; US20140186958; US20140186919; US20140186843; US20140179770; US20140179006; US20140170753; WO / 2008 / 108989; WO / 2010 / 054108; WO / 2012 / 164565; WO / 2013 / 098244; WO / 2013 / 176772; US 20150071899; Makarova et al., "Evolution and classification of the CRISPR-Cas systems" 9(6) Nature Reviews Microbiology 467-477 (1-23) (June 2011); Wiedenheft et al., "RNA-guided genetic silencing systems in bacteria and archaea" 482 Nature 331-338 (February 16, 2012);Gasiunas et al., "Cas9-crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteria" 109(39) Proceedings of the National Academy of Sciences USA E2579-E2586 (September 4, 2012); Jinek et al., "A Programmable Dual-RNA-Guided DNA Endonuclease in Adaptive Bacterial Immunity" 337 Science 816-821 (August 17, 2012); Carroll, "A CRISPR Approach to Gene Targeting" 20(9) Molecular Therapy 1658-1660 (September 2012); U.S. application No. 61 / 652,086 filed May 25, 2012; Al-Attar et al., Clustered Regularly Interspaced Short Palindromic Repeats (CRISPRs): The Hallmark of an Ingenious Antiviral Defense Mechanism in Prokaryotes, Biol Chem. (2011) Vol. 392, No. 4, pp. 277-289; Hale et al., Essential Features and Rational Design of CRISPR RNAs That Function With the Cas RAMP Module Complex to Cleave RNAs, Molecular Cell, (2012) Vol. 45, No. 3, pp. 292-302.
[0086] In some embodiments, the fusion protein comprises a linker between a DNA binding domain (e.g., ZFN, TALE or nCas9) and a BE domain. The linker that can be used for these fusion proteins (or between fusion proteins of a tandem structure) can comprise any sequence that does not interfere with the function of the fusion protein. In a preferred embodiment, the linker is short, for example, 2-20 amino acids, and is generally flexible (i.e., comprising amino acids with a high degree of freedom, such as glycine, alanine and serine). In some embodiments, the linker comprises one or more units consisting of GGGS (SEQ ID NO: 46) or GGGGS (SEQ ID NO: 47), for example, two, three, four or more repeats of GGGS (SEQ ID NO: 47) or GGGGS (SEQ ID NO: 46) units. Other linker sequences can also be used.
[0087] In some embodiments, the split deaminase fusion protein comprises a cell penetrating peptide sequence that facilitates delivery to the intracellular space, e.g., an HIV-derived TAT peptide, a penetratin, a transportan, or an hCT-derived cell penetrating peptide, e.g., see, Caron et al., (2001) Mol Ther. 3(3):310-8; Langel, Cell-Penetrating Peptides: Processes and Applications (CRC Press, Boca Raton FL 2002); El-Andaloussi et al., (2005) Curr Pharm Des. 11(28):3597-611; and Deshayes et al., (2005) Cell Mol Life Sci. 62(16):1839-49.
[0088] Cell penetrating peptides (CPPs) are short peptides that facilitate the movement of a wide variety of biomolecules across cell membranes into the cytoplasm or other organelles, such as mitochondria and nuclei. Examples of molecules that can be delivered by CPPs include therapeutic drugs, plasmid DNA, oligonucleotides, siRNA, peptide nucleic acids (PNA), proteins, peptides, nanoparticles, and liposomes. CPPs are typically 30 amino acids or less, derived from naturally or non-naturally occurring proteins or chimeric sequences, containing high relative abundance of positively charged amino acids, such as lysine or arginine, or alternating patterns of polar and non-polar amino acids. Commonly used CPPs in the art include Tat (Frankel et al., (1988) Cell. 55: 1189-1193; Vives et al., (1997) J. Biol. Chem. 272: 16010-16017), penetratin (Derossi et al., (1994) J. Biol. Chem. 269: 10444-10450), polyarginine peptide sequences (Wender et al., (2000) Proc. Natl. Acad. Sci. USA 97: 13003-13008; Futaki et al., (2001) J. Biol. Chem. 276: 5836-5840), and transporters (Pooga et al., (1998) Nat. Biotechnol. 16: 857-861).
[0089] CPPs can be linked to their cargoes by covalent or non-covalent strategies. Methods for covalently linking CPPs and their cargoes are known in the art, such as chemical cross-linking (Stetsenko et al., (2000) J. Org. Chem. 65: 4900-4909; Gait et al., (2003) Cell. Mol. Life. Sci. 60: 844-853) or cloning fusion proteins (Nagahara et al., (1998) Nat. Med. 4: 1449-1453). Non-covalent coupling between cargoes and short amphipathic CPPs containing polar and non-polar domains is established by electrostatic and hydrophobic interactions.
[0090] CPPs have been utilized in the art to deliver potentially therapeutic biomolecules to cells. Examples include cyclosporine linked to polyarginine for immunosuppression (Rothbard et al., (2000) Nature Medicine 6(11):1253-1257), siRNA against cyclin B1 linked to a CPP, called MPG, for inhibiting tumor formation (Crombez et al., (2007) Biochem Soc. Trans. 35:44-46), the tumor suppressor p53 peptide linked to a CPP to reduce cancer cell growth (Takenobu et al., (2002) Mol. Cancer Ther. 1(12):1043-1049; Snyder et al., (2004) PLoS Biol. 2:E36), and a dominant negative form of Ras fused to Tat or phosphoinositide 3-kinase (PI3K) to treat asthma (Myou et al., (2003) J. Immunol. 171:4399-4405).
[0091] CPPs have been used in the art to transport contrast agents into cells for imaging and biosensing applications. For example, green fluorescent protein (GFP) attached to Tat has been used to label cancer cells (Shokolenko et al., (2005) DNA Repair 4(4):511-518). Tat conjugated to quantum dots has been used to successfully cross the blood-brain barrier to visualize the rat brain (Santra et al., (2005) Chem. Commun. 3144-3146). CPPs have also been combined with magnetic resonance imaging techniques for cell imaging (Liu et al., (2006) Biochem. and Biophys. Res. Comm. 347(1):133-140). See also Ramsey and Flynn, Pharmacol Ther. 2015 Jul 22. pii:S0163-7258(15)00141-2.
[0092] Alternatively or additionally, the split deaminase fusion protein may comprise a nuclear localization sequence, e.g., SV40 large T antigen NLS (PKKKRRV (SEQ ID NO: 48)) and nucleoplasmin NLS (KRPAATKKAGQAKKKK (SEQ ID NO: 49)). Other NLSs are known in the art; for example, see Cokol et al., EMBO Rep. 2000 Nov 15; 1(5): 411–415; Freitas and Cunha, Curr Genomics. 2009 Dec; 10(8): 550–557.
[0093] In some embodiments, the split deaminase fusion protein includes a portion with high affinity for a ligand such as a GST sequence, a FLAG sequence, or a hexahistidine sequence. Such an affinity tag can facilitate the purification of the recombinant split deaminase fusion protein.
[0094] For methods in which the split deaminase fusion protein is delivered to a cell, the split deaminase fusion protein can be produced using any method known in the art, for example, by in vitro translation, or expression in a suitable host cell from a nucleic acid encoding the split deaminase fusion protein; many methods of producing proteins are known in the art. For example, the protein can be produced and purified in yeast, E. coli, insect cell lines, plants, transgenic animals, or cultured mammalian cells; for example, see Palomares et al., "Production of Recombinant Proteins: Challenges and Solutions," Methods Mol Biol. 2004; 267: 15-52. In addition, the split deaminase fusion protein can be linked to a moiety that facilitates transfer into the cell, for example, a lipid nanoparticle, optionally using a linker that is cleaved once the protein is inside the cell. For example, see LaFountaine et al., Int J Pharm. 2015 Aug 13; 494(1): 180-194.
[0095] Expression system
[0096] In order to use the split deaminase fusion proteins described herein, it may be desirable to express these variants from nucleic acids encoding them. This can be done in a variety of ways. For example, nucleic acids encoding the split deaminase fusions can be cloned into intermediate vectors for transformation into prokaryotic or eukaryotic cells for replication and / or expression. The intermediate vector is generally a prokaryotic vector, e.g., a plasmid, or a shuttle vector, or an insect vector, for storage or manipulation of nucleic acids encoding the split deaminase fusions for production of the split deaminase fusion proteins. Nucleic acids encoding the split deaminase fusion proteins can also be cloned into expression vectors for administration to plant cells, animal cells, preferably mammalian cells or human cells, fungal cells, bacterial cells, or protozoan cells.
[0097] To obtain expression, the sequence encoding the split deaminase fusion protein is generally subcloned into an expression vector containing a promoter that directs transcription. Suitable bacterial and eukaryotic promoters are well known in the art, for example, in Sambrook et al., Molecular Cloning, A Laboratory Manual (3d ed. 2001); Kriegler, Gene Transfer and Expression: A Laboratory Manual (1990); and Current Protocols in Molecular Biology (Ausubel et al., 2010). Bacterial expression systems for expressing engineered proteins can be obtained from, for example, Escherichia coli, Bacillus sp., and Salmonella (Palva et al., 1983, Gene 22: 229-235). Kits for such expression systems are commercially available. Eukaryotic expression systems for mammalian cells, yeast, and insect cells are well known in the art and are also commercially available.
[0098] The promoter used to direct the expression of the nucleic acid depends on the specific application. For example, strong constitutive promoters are generally used for the expression and purification of fusion proteins. In contrast, when the split deaminase fusion protein is to be administered in vivo for gene regulation, a constitutive or inducible promoter may be used, depending on the specific application of the split deaminase fusion protein. In addition, a preferred promoter for the administration of the split deaminase fusion protein may be a weak promoter, such as HSV TK or a promoter with similar activity. The promoter can also contain elements that respond to transactivation, for example, hypoxia response elements, Gal4 response elements, lac repressor response elements, and small molecule control systems, such as the tetracycline-regulated system and the RU-486 system (see, for example, Gossen and Bujard, 1992, Proc. Natl. Acad. Sci. USA, 89:5547; Oligino et al., 1998, Gene Ther., 5:491-496; Wang et al., 1997, Gene Ther., 4:432-441; Neering et al., 1996, Blood, 88:1147-55; and Rendahl et al., 1998, Nat. Biotechnol., 16:757-761).
[0099] In addition to the promoter, the expression vector generally contains a transcription unit or expression cassette, which contains all other elements required for the expression of the nucleic acid in a prokaryotic or eukaryotic host cell. Thus, a typical expression cassette contains a promoter, which is operably linked to, for example, a nucleic acid sequence encoding the split deaminase fusion protein, and any signals required, for example, for efficient polyadenylation of the transcript, transcriptional termination, ribosome binding sites, or translation termination. Additional elements of the expression cassette may include, for example, enhancers and intronic signals for heterologous splicing.
[0100] The specific expression vector used to transport genetic information into cells is selected according to the intended use of the split deaminase fusion protein, for example, expression in plants, animals, bacteria, fungi, protozoa, etc. Standard bacterial expression vectors include plasmids, such as pBR322-based plasmids, pSKF, pET23D, and commercially available tag fusion expression systems such as GST and LacZ.
[0101] Expression vectors containing regulatory elements from eukaryotic viruses are often used in eukaryotic expression vectors, for example, SV40 vectors, papillomavirus vectors, and vectors from Epstein-Barr virus. Other exemplary eukaryotic vectors include pMSG, pAV009 / A+, pMTO10 / A+, pMAMneo-5, baculovirus pDSVE, and any other vector that allows protein expression under the direction of the SV40 early promoter, SV40 late promoter, metallothionein promoter, mouse mammary tumor virus promoter, Rous sarcoma virus promoter, polyhedrin promoter, or other promoters that have shown expression effectiveness in eukaryotic cells.
[0102] The vector for expressing the split deaminase fusion protein can contain an RNA Pol III promoter to drive the expression of the guide RNA, for example, H1, U6 or 7SK promoter. These human promoters allow the split deaminase fusion protein to be expressed in mammalian cells after plasmid transfection.
[0103] Some expression systems have markers for selection of stably transfected cell lines, such as thymidine kinase, hygromycin B phosphotransferase, and dihydrofolate reductase. High-yield expression systems are also suitable, for example, using baculovirus vectors in insect cells and the gRNA encoding sequence under the direction of the polyhedrin promoter or other strong baculovirus promoters.
[0104] Elements generally included in expression vectors also include a replicon that functions in E. coli, genes encoding antibiotic resistance to allow selection of bacteria carrying the recombinant plasmid, and unique restriction sites in noncritical regions of the plasmid to allow insertion of the recombinant sequence.
[0105] Standard transfection methods are used to generate bacterial, mammalian, yeast or insect cell lines that express large amounts of protein, followed by purification using standard techniques (e.g., see Colley et al., 1989, J. Biol. Chem., 264: 17619-22; Guide to Protein Purification, cited in Methods in Enzymology, Vol. 182 (Deutscher, 1990). Transformation of eukaryotic and prokaryotic cells is performed according to standard techniques (e.g., see Morrison, 1977, J. Bacteriol. 132: 349-351; Clark-Curtiss and Curtiss, Methods in Enzymology 101: 347-362 (Wud et al., 1983).
[0106] Any known method for introducing exogenous nucleotide sequences into host cells can be used. These methods include the use of calcium phosphate transfection, polybrene, protoplast fusion, electroporation, nucleofection, liposomes, microinjection, naked DNA, plasmid vectors, viral vectors (free and integrated) and any other known methods for introducing cloned genomic DNA, cDNA, synthetic DNA or other exogenous genetic material into host cells (e.g., see Sambrook et al., supra). It is only necessary that the specific genetic engineering method used is capable of successfully introducing at least one gene into a host cell that can express the split deaminase fusion protein.
[0107] Alternatively, these methods may include delivering the split deaminase fusion protein and guide RNA together, for example, as a complex. For example, the split deaminase fusion protein and gRNA can be overexpressed and purified in a host cell, then compounded with the guide RNA (e.g., in a test tube) to form a ribonucleoprotein (RNP), and delivered to the cell. In some embodiments, the split deaminase fusion protein can be expressed in bacteria and purified therefrom using a bacterial expression plasmid. For example, the split deaminase fusion protein with a His tag can be expressed in bacterial cells and then purified using nickel affinity chromatography. The use of RNPs circumvents the necessity of delivering plasmid DNA encoding nucleases or guides in the form of plasmid DNA or mRNA encoding nucleases. RNP delivery can also improve specificity, presumably because the half-life of RNPs is short and there is no persistent expression of nucleases and guides (as would be obtained from a plasmid). For example, RNPs can be delivered to cells in vivo or in vitro using lipid-mediated transfection or electroporation. For example, see Liang et al. "Rapid and highly efficient mammalian cell engineering via Cas9 protein transfection." Journal of biotechnology 208 (2015): 44-53; Zuris, John A. et al. "Cationic lipid-mediated delivery of proteins enables efficient protein-based genome editing in vitro and in vivo." Nature biotechnology 33.1 (2015): 73-80; Kim et al. "Highly efficient "RNA-guided genome editing in human cells via delivery of purifiedCas9 ribonucleoproteins." Genome research 24.6(2014):1012-1019.
[0108] The invention also includes vectors and cells comprising vectors, for example, for use in the methods described herein, and kits comprising the proteins and nucleic acids described herein.
[0109] Treating beta thalassemia
[0110] Beta thalassemia is a group of genetic diseases characterized by an inherited deficiency in the synthesis of beta-globin chains. Thalassemia major, in which the affected individual is homozygous for the mutation, is associated with severe anemia requiring blood transfusions. Thalassemia minor is the least severe and generally does not require treatment, while those with severity levels between thalassemia minor and thalassemia major are said to have thalassemia intermedia. See, e.g., Cao and Galanello, Genetics in Medicine 12, 61–76 (2010).
[0111] hAPOBEC3A mutants, e.g., N57G or N57A or N57Q or K60A or K60D or Y130F, as fusion proteins in the BE3 structure as described herein, can be used as therapeutics, e.g., in subjects with the beta-thalassemia mutation HBB-28 (A>G) commonly found in some East Asian populations (see Liang et al., Protein Cell. 2017 Nov; 8(11): 811-822). Methods for identifying subjects with this mutation are known in the art; e.g., see Saetung et al., Southeast Asian J Trop Med Public Health. 2013 Nov; 44(6): 1055-64; Liu et al., Hemoglobin. 2015; 39(1): 18-23; Doro et al., Hemoglobin. 2017 Mar; 41(2): 96-99; Zhang et al., BMJ Open. 2017 Jan 31; 7(1): e013367. These methods may include mobilizing and subsequently extracting CD34+ hematopoietic stem cells and progenitor cells (HSPCs) (e.g., see Bonig and Papayannopoulou, Methods Mol Biol. 2012; 904: 1–14; Jin et al., BioMed Research International, Vol. 2014, Paper ID 435215, 9 pages, 2014). HSPCs are then modified ex vivo (outside the subject's body) by introducing mRNA encoding a base editor protein or by using a purified base editor protein + guide (e.g., RNP). Before the modified cells are returned to the subject, the cultured cells can be maintained to allow proliferation, for example, for several days. The subject may also undergo bone marrow cell removal before infusion to ensure that the modified cells are well engrafted (see Sullivan, Keith M. et al., New England Journal of Medicine 378.1 (2018): 35-47.). The modified stem cells are then allowed to migrate into the subject's bone marrow and produce red blood cells without beta thalassemia.
[0112] As described herein, we investigated whether APO3A N57G BE3 could efficiently induce single nucleotide editing at the HBB-28 (A>G) allele that causes β-thalassemia, which is common in some East Asian populations. We first generated a HEK293T model cell line carrying a single integrated 200 bp fragment of the pathogenic HBB-28 (A>G) promoter allele and tested whether APO3A N57G BE3 could more efficiently induce single nucleotide editing at the -28 (A>G) position (editing on the antisense strand to affect the sense strand) relative to BE3 or YE BE3 derivatives. As expected, APO3A N57G BE3 induced significantly fewer editing events at the HBB-25 bystander motif while retaining high editing activity at the -28 (A>G) homologous motif. Editing with BE3 resulted in 0.57% perfectly corrected alleles. Deamination of HBB-25 cytidine by BE3 in the editing window produced 11.5% and 1.8% of the causal β-thalassemia mutations HBB-25(G>T) and (G>C) mutations in the alleles, respectively. The product -25(G>A), which accounts for 15.2% of the total alleles after editing with BE3, can also produce an independent β-thalassemia phenotype, but this has yet to be clinically confirmed. In contrast, editing at the HBB-28(A>G) site with APO3AN57G BE3 produced 22.5% perfectly corrected alleles, 40-fold more than BE3, and produced a total editing rate of 3.96% at the -25 position.
[0113] Example
[0114] The present invention is further described in the following examples, which do not limit the scope of the invention described in the claims.
[0115] Materials and methods
[0116] Plasmids and oligonucleotides
[0117] BE expression plasmids containing amino acid substitutions were generated by PCR and standard molecular cloning methods. gRNA expression plasmids were constructed by ligating annealed oligonucleotide duplexes to BsmBI-cleaved MLM3636. All gRNAs were designed to target sites containing 5′ guanine nucleotides, except those targeting HBB-28 (A>G) and CTNNB1 sites.
[0118] Human cell culture and transfection
[0119] 2OS.EGFP cells and HEK293T cells containing a single stably integrated copy of the EGFP-PEST reporter gene were cultured in DMEM supplemented with 10% heat-inactivated fetal bovine serum, 2 mM GlutaMax, penicillin, and streptomycin at 37°C and 5% CO2. The culture medium of U2OS.EGFP cells was supplemented with 400 μg ml -1 Geneticin. Cell line identity was verified by STR analysis (ATCC) and cells were regularly tested for mycoplasma contamination. U2OS.EGFP cells were transfected with 750ng of plasmid expressing BE and 250ng of plasmid expressing sgRNA using the DN-100 program and SE cell line kit on the Lonza 4-D Nucleofector according to the manufacturer's recommendations. For HEK293T transfection, 75,000 cells were seeded in 24-well plates and 18 hours later, according to the manufacturer's recommendations, TransIT-293 (Mirus) was used to transfect with 600ng of plasmid expressing BE and 200ng of plasmid expressing sgRNA. For all targeted amplicon sequencing and GUIDE-seq experiments, genomic DNA was extracted 72 hours after transfection. Cells were lysed in a lysis buffer containing 100 mM Tris-HCl pH 8.0, 150 mM NaCl, 5 mM EDTA and 0.05% SDS and incubated overnight in an incubator at 55° C. with shaking at 250 rpm. Genomic DNA was extracted from lysed cells using carboxyl-modified Sera-Mag fast magnetic beads (Magnetic Speed-beads) (magnetic beads) resuspended in 2.5 M NaCl and 18% PEG-6000.
[0120] The HEK293T.HBB cell line was constructed in a lentiviral vector by cloning a 200 base pair fragment of the HBB promoter upstream of the EF1a promoter driving the expression of the puromycin resistance gene. The HBB-28 (A>G) mutation was inserted by PCR and standard molecular cloning methods. The lentiviral vector was transfected into 293FS cells and the medium containing the viral particles was harvested after 72 hours. The medium containing the viral particles was serially diluted and added to 10 cm plates at approximately 10 million HEK293T cells. After 48 hours, the medium was supplemented with 2.5 μg ml -1 Puromycin was added and cells were harvested from the 10-cm plate with the fewest surviving colonies to ensure single-copy integration.
[0121] Off-target site selection and amplicon design
[0122] Two of the sites characterized here, EMX1 site 1 and FANCF, have been previously characterized by the modified Digenome-seq method, an unbiased approach to discover BE3-specific off-target sites. All off-targets discovered by the modified Digenome-seq method were investigated, and these sites represent the most comprehensive off-target characterization because they were discovered de novo using BE3. The VEGFA site 2 target is a promiscuous homopolymeric gRNA previously characterized by the GUIDE-seq method. Because the VEGFA site 2 gRNA has over a hundred nuclease off-target sites, we selected the 20 off-target sites with the highest number of GUIDE-seq reads that were also located in the loci for which we were able to design unique PCR amplification primers for the characterization herein. The CTNNB1 and HBB-28 (A>G) gRNAs have not been previously characterized for BE or nuclease off-target sites. Using these gRNAs, we performed GUIDE-seq as previously described. 17 To identify off-target sites for the SpCas9 nuclease, Cas-OFFinder was used to predict all potential off-target sites with one RNA bulge and one mismatch. (GUIDE-seq and Cas-OFFinder analysis were performed using the hg38 reference genome) This type of off-target is more prevalent in BE3 than in the nuclease. 16 , and thus more prevalent in sites that we are unlikely to find by GUIDE-seq. Primers were designed to amplify all off-target sites so that the potential cytidines edited were within the first 100 base pairs of IlluminaHTS reads. A total of six primer pairs covering the off-target sites of EMX1 site 1, VEGFA site 2, and CTNNB1 site 1 did not amplify their expected amplicons and were therefore excluded from further analysis.
[0123] Statistical tests
[0124] All statistical tests were performed using two-tailed Student's t-test according to the method of Benjamini, Krieger, and Yekutieli, assuming no equal variances between samples.
[0125] Targeted Amplicon Sequencing
[0126] On-target and off-target sites were amplified from approximately 100 ng of genomic DNA from three biological replicates of each condition. PCR amplification was performed using Phusion high-fidelity DNA polymerase (NEB). 50 μl PCR reactions were purified using 1x volume magnetic beads. Amplification fidelity was verified by capillary electrophoresis on a Qiaxcel instrument. Amplicons with orthogonal sequences were pooled for each three-repeat transfection, and NEBNext Ultra II DNA library preparation kits were used according to the manufacturer's instructions, with Illumina flow cell compatibility adapters added. Primers from NEBNext Multiplex Oligos for Illumina (Dual Index Primers Set 1) were used, and Illumina i5 and i7 indexes were added by additional 10 PCR cycles using Q5 high-fidelity DNA polymerase, and purified using 0.7x volume magnetic beads. The final amplicon library containing Illumina compatible adapters and indexes was quantified by droplet digital PCR and sequenced on an Illumina MiSeq instrument using 150 bp paired-end reads. The sequencing reads were demultiplexed by MiSeq Reporter and the base frequency at each position was subsequently analyzed by CRISPResso Rev. 28 Indels were quantified in a 10-bp window surrounding the expected cut site for each sgRNA.
[0127] Expression of HBB-28(A>G) gRNA
[0128] To use eA3A BE with HF1 or Hypa mutations to reduce genome-wide off-target editing, a 20-nucleotide spacer sequence in the gRNA with no mismatch between the spacer and the target site must be used. We expressed the HBB-28(A>G) gRNA from a plasmid using the U6 promoter that preferentially initiates transcription at a guanine nucleotide at the +1 position. To protect a perfect match between the spacer and the target site, we attached a self-cleaving 5' hammerhead ribozyme that is able to remove mismatched guanines 5' to the spacer.
[0129] Exemplary protein sequences
[0130] rAPOBEC1-XTEN L8-nCas9-UGI-SV40 NLS
[0131]
[0132] Uracil glycosylase inhibitors (UGI)
[0133] TNLSDIIEKETGKQLVIQESILMLPEEVEEVIGNKPESDILVHTAYDEST DENVMLLTSDAPEYKPWALVIQDSNGENKIKML(SEQ ID NO:45)
[0134] hAID
[0135] MDSLLMNRKFLYQFKNVRWAKGRRETYLCYVVKRRDSATSSFLDFGYLRNKNGCHVELLFLRYISDWDLDPGRCYRVTWFTSWSPCYDCARHVADFLRGNPNLSLRIFTARLYFCEDRKAEPEGLRRLHRAGVQIAIMTFKDYFYCWNTFVENHERTFKAWEGLHENSVRLSRQLRRILLPLYEVDDLRDAFRTLGL(SEQ ID NO:51)
[0136] Solubility variant of hAIDv lacking the N-terminal RNA binding region
[0137] MDPHIFTSNFNNGIGRHKTYLCYEVERLDSATSFSLDFYLRNKNGCHVELLFLRYISDWDLDPGRCYRVTWFTSWSPCYDCARHVADFLRGNPNLSLRIFTARLYFCEDRKAEPEGLRRLHRAGVQIAIMTFKDYFYCWNTFVENHERTFKAWEGLHENSVRLSRQLRRILLPLYEVDDLRDAFRTLGL(SEQ ID NO:52)
[0138] Solubility variant of hAIDv lacking the N-terminal RNA binding region and the C-terminal poorly structured region
[0139] MDPHIFTSNFNNGIGRHKTYLCYEVERLDSATSFSLDFGYLRNKNGCHVELLFLRYISDWDLDPGRCYRVTWFTSWSPCYDCARHVADFLRGNPNLSLRIFTARLYFCEDRKAEPEGLRRLHRAGVQIAIMTFKDYFYCWNTFVENHERTFKAWEGLHENSVRLSRQLRRILLPL(SEQ ID NO:53)
[0140] rAPOBEC1
[0141] MSSETGPVAVDPTLRRRIEPHEFEVFFDPRELRKETCLLYEINWGGRHSIWRHTSQNTNKHVEVNFIEKFTTERYFCPNTRCSITWFLSWSPCGECSRAITEFLSRYPHVTLFIYIARLYHHADPRNRQGLRDLISSGVTIQIMTEQESGYCWRNFVNYSPSNEAHWPRYPHLWVRLYVLELYCIILGLPPCLNILRRKQPQLTFFTIALQSCHYQRLPPHILWATGLK(SEQ ID NO:54)
[0142] mAPOBEC3
[0143] MGPFCLGCSHRKCYSPIRNLISQETFKFHFKNLGYAKGRKDTFLCYEVTRKDCDSPVSLHHGVFKNKDNIHAEICFLYWFHDKVLKVLSPREEFKITWYMSWSPCFECAEQIVRFLATHHNLSLDIFSSRLYNVQDPETQQNLCRLVQEGAQVAAMDLYEFKKCWKKFVDNGGRRFRPWKRLLTNFRYQDSKLQEILRRMDPLSEEEFYSQFYNQRVKHLCYYHRMKPYLCYQLEQFNGQAPLKGCLLSEKGKQHAEILFLDKIRSMELSQVTITCYLTWSPCPNCAWQLAAFKRDRPDLILHIYTSRLYFHWKRPFQKGLCSLWQSGILVDVMDLPQFTDCWTNFVNPKRPFRPWKGLEIISRRTQRRLRRIKESWGLQDLVNDFGNLQLGPPMSN(SEQ ID NO:55)
[0144] mAPOBEC3 catalytic domain
[0145] MGPFCLGCSHRKCYSPIRNLISQETFKFHFKNLGYAKGRKDTFLCYEVTRKDCDSPVSLHHGVFKNKDNIHAEICFLYWFHDKVLKVLSPREEFKITWYMSWSPCFECAEQIVRFLATHHNLSLDIFSSRLYNVQDPETQQNLCRLVQEGAQVAAMDLYEFKKCWKKFVDNGGRRFRPWKRLLTNFRYQDSKLQEILRR(SEQ ID NO:56)
[0146] hAPOBEC3A
[0147] MEASPASGPRHLMDPHIFTSNFNNGIGRHKTYLCYEVERLDNGTSVKMDQHRGFLHNQAKNLLCGFYGRHAELRFLDLVPSLQLDPAQIYRVTWFISWSPCFSWGCAGEVRAFLQENTHVRLRIFAARIYDYDPLYKEALQMLRDAGAQVSIMTYDEFKHCWDTFVDHQGCPFQPWDGLDEHSQALSGRLRAILQNQGN(SEQ ID NO:57)
[0148] hAPOBEC3G
[0149] MKPHFRNTVERMYRDTFSYNFYNRPILSRRNTVWLCYEVKTKGPSRPPLDAKIFRGQVYSELKYHPEMRFFHWFSKWRKLHRDQEYEVTWYISWSPCTKCTRDMATFLAEDPKVTLTIFVARLYYFWDPDYQEALRSLCQKRDGPRATMKIMNYDEFQHCWSKFVYSQRELFEPWNNLPKYYILLHIMLGEILRHSMDPPTFTFNFNNEPWVRGRHETYLCYEVERMHNDTWVLLNQRRGFLCNQAPHKHGFLEGRHAELCFLDVIPFWKLDLDQDYRVTCFTSWSPCFSCAQEMAKFISKNKHVSLCIFTARIYDDQGRCQEGLRTLAEAGAKISIMTYSEFKHCWDTFVDHQGCPFQPWDGLDEHSQDLSGRLRAILQNQEN(SEQ ID NO:58)
[0150] hAPOBEC3G catalytic domain
[0151] PPTFTFNFNNEPWVRGRHETYLCYEVERMHNDTWVLLNQRRGFLCNQAPHKHGFLEGRHAELCFLDVIPFWKLDLDQDYRVTCFTSWSPCFSCAQEMAKFISKNKHVSLCIFTARIYDDQGRCQEGLRTLAEAGAKISIMTYSEFKHCWDTFVDHQGCPFQPWDGLDEHSQDLSGRLRAILQNQEN(SEQ ID NO:59)
[0152] hAPOBEC3H
[0153] MALLTAETFRLQFNNKRRLRRPYYPRKALLCYQLTPQNGSTPTRGYFENKKKCHAEICFINEIKSMGLDETQCYQVTCYLTWSPCSSCAWELVDFIKAHDHLNLGIFASRLYYHWCKPQQKGLRLLCGSQVPVEVMGFPKFADCWENFVDHEKPLSFNPYKMLEELDKNSRAIKRRLERIKIPGVRAQGRYMDILCDAEV(SEQ ID NO:60)
[0154] hAPOBEC3F
[0155] MKPHFRNTVERMYRDTFSYNFYNRPILSRRNTVWLCYEVKTKGPSRPRLDAKIFRGQVYSQPEHHAEMCFLSWFCGNQLPAYKCFQITWFVSWTPCPDCVAKLAEFLAEHPNVTLTISAARLYYYWERDYRRALCRLSQAGARVKIMDDEEFAYCWENFVYSEGQPFMPWYKFDDNYAFLHRTLKEILRNPMEAMYPHIFYFHFKNLRKAYGRNESWLCFTMEVVKHHSPVSWKRGVFRNQVDPETHCHAERCFLSWFCDDILSPNTNYEVTWYTSWSPCPECAGEVAEFLARHSNVNLTIFTARLYYFWDTDYQEGLRSLSQEGASVEIMGYKDFKYCWENFVYNDDEPFKPWKGLKYNFLFLDSKLQEILE(SEQ ID NO:61)
[0156] hAPOBEC3F catalytic domain
[0157] KEILRNPMEAMYPHIFYFHFKNLRKAYGRNESWLCFTMEVVKHHSPVSWKRGVFRNQVDPETHCHAERCFLSWFCDDILSPNTNYEVTWYTSWSPCPECAGEVAEFLARHSNVNLTIFTARLYYFWDTDYQEGLRSLSQEGASVEIMGYKDFKYCWENFVYNDDEPFKPWKGLKYNFLFLDSKLQEILE(SEQ ID NO:62)
[0158] Staphylococcus aureus (S. aureus) Cas9
[0159]
[0160] Campylobacter jejuni (C.jejuni) Cas9
[0161] (SEQ ID NO:64)
[0162] P. lavamentivorans Cas9
[0163]
[0164] Neisseria cinerea Cas9
[0165]
[0166] Campylobacter lari Cas9
[0167]
[0168] Example 1. Improving the genome-wide specificity of targeted base editing technology
[0169] The wild-type cytidine deaminase domain has an intrinsic substrate sequence specificity for a 2-3 nucleotide motif (see Table 1). APOBEC enzymes recognize their cognate sequence motifs through direct contacts formed between residues in two recognition loops with variable sequence composition, called recognition loop 1 (RL1) and loop 7. 12-13 , 17-22 (See Table 2, Figure 2A-2B and Figure 3A-3B ). For example, a major determinant of APO3A substrate sequence specificity is residue D131 in loop 7, which makes two hydrogen bonds with thymine in the 5' TC motif. To modulate the specificity of APO3A, we changed the identity of the residue at position 131 to a residue that has been previously shown to form base-specific contacts (Table 7) 43 .
[0170] To alter the specificity of all other APOBEC deaminases listed in Table 1, we altered homologous residues from each of these proteins identified by alignment with the APO3A sequence.
[0171] Although wild-type APO3A has inherent sequence specificity for the 5'TcR motif, it can deaminize the 5'AcR, 5'GcR, and 5'CcR motifs (where lowercase C is the base being deaminated) at lower efficiency. This suggests that it may be possible to engineer APO3A to have greater specificity for its canonical TcR substrate motif by removing excess binding energy in the form of contacts formed between APO3A and its substrate ssDNA, thereby efficiently deaminating only TcG or TcA motifs. Crystal structure of APO3A bound to substrate ssDNA 21We identified R28 and K30 (which appear to contact the base immediately 3' of the Tc in a semi-specific manner) and N57, R60, and Y130 (which all contact the ssDNA substrate backbone in a non-base specific manner) as candidate residues whose DNA contacts may contribute significant non-specific substrate binding energy, such that altering them may result in a more specific deaminase. We have also identified W98 as a residue that contributes to the formation of a hydrophobic pocket into which the target cytosine base is buried, and hypothesized that W98Y would reduce the hydrophobicity of this pocket while retaining deaminase activity, thereby reducing any possible excess binding energy above that required for deamination of the Tc motif. Because multiple APOBEC homologs and orthologs have significant similarity to APO3A at the sequence level, we have also identified homologous residues that are expected to increase substrate sequence specificity for each of these proteins.
[0172] To test mutations that we hypothesized could contribute to increased specificity of engineered base-editing proteins for TcR motifs, we cloned the gene encoding the APO3A-nCas9-UGI protein carrying a single residue substitution in APO3A into a plasmid vector used to overexpress the protein in mammalian cells. We then transfected these plasmid vectors into human U2OS cells in combination with a plasmid designed to express a guide RNA targeting one of two independent sites, carrying multiple trinucleotide motifs capable of functioning as substrates for internal deamination of a single integrated EGFP gene. After 72 hours, we harvested genomic DNA from the transfected U2OS population and performed high-throughput amplicon sequencing at the guide RNA genomic target site. We found that when the wild-type APO3A protein was fused to nCas9-UGI, the resulting protein was able to achieve C>T conversion at the target site of the expected TcR motif, and also achieved this conversion for GcT and GcG motifs present at the target site ( Figure 4 ). However, when N57 or K60 were mutated to the residues listed in Table 7, we observed robust deamination at the on-target TcG present in the editing window, but observed a significant reduction in the ability of these proteins to target motifs outside the base editing window and at the GcT motif present in the editing window. Notably, APO3A N57A-nCas9-UGI and APO3A K60D-nCas9-UGI retained robust activity for the editing window TcG, but retained low to very low activity for the editing window GcT motif ( Figure 5 To quantitatively evaluate this increased preference for TcG over GcT in EGFP site 1 in the editing window, we divided the deamination frequency at the TcG motif in the editing window by the deamination frequency at the GcT motif in the editing window to determine the specificity ratio of these proteins ( Figure 6). We found that both APO3A N57A-nCas9-UGI and APO3A K60D / E / N-nCas9-UGI had demonstrated increased specificity for the TcG motif relative to the GcT motif, relative to the wild-type APO3A-nCas9-UGI protein. We then evaluated the activity of these proteins at EGFP site 2 (a target site carrying GcA, AcA, AcC, CcC, CcA, and GcG motifs as well as the TcG motif outside the editing window). Each of the aforementioned mutants demonstrated significantly reduced activity against each of these off-target motifs in the target site, as well as reduced activity against the on-target TCG motif found outside the editing window ( Figure 7 , Figure 8 ).
[0173] Crystal structure of APO3A in complex with its ssDNA substrate 21 , we determined that K30 makes base-specific contacts with the third nucleotide in the TcG motif. We hypothesized that mutations to the residue at this position would alter the identity of the third nucleotide in the trinucleotide substrate motif that is recognized by APO3A-nCas9-UGI. Because we expect the identity of the residue at position 30 to significantly influence the identity of the third nucleotide in the substrate motif, we have identified residues that we expect to make contacts with specific bases in Table 9.
[0174] When the resulting plasmid DNA encoding the base editor protein was delivered to human cells by transient transfection together with a plasmid encoding a gRNA targeting the chromosomally integrated EGFP gene, mutations made to multiple residues in APO3A (Table 9) were able to restore sequence preference to varying degrees ( Fig. 9 We also found that the specificity of APO3A for its cognate 5'TC motif can be enhanced by combining mutations at the positions listed in Table 7 and targeting the BE proteins to the same EGFP target site by transient plasmid transfection, generating APO3A N57Q / Y130F BE3 variants with similar motif specificity for APO3A N57A or N57G BE3 ( Fig.10 ).
[0175] We screened the activity of APO3A N57A or N57G or (N57Q / Y130F) BE3 at 12 endogenous genomic sites containing a homologous 5' TC motif in the editing window in addition to another non-homologous 5' VC (where V = A, C or G) and compared them with BE3 and prior art engineered variants YE1, YE2 and YEE BE3 (YE BE3) that reduced the frequency of such bystander mutations by incorporating point mutations into the rat APOBEC1 (rAPO1) deaminase domain that slowed its kinetic rate and limited its editing window length compared to BE3 44 We found that at 8 of the 12 sites, the engineered APO3A BE3 variants induced 5-fold to 264-fold more C to T editing at the cognate motif than at the noncognate 5' VC motif ( Figure 11-Figure 12 ). However, the engineered APO3A BE3 variant induced homologous:non-homologous editing at the remaining 4 sites at a ratio of less than 5.
[0176] Next, we sought to improve sequence-specific deamination of APO3A N57G BE3 by adding mutations to residues previously shown to affect the catalytic rate and processivity of homologous proteins (Table 10). Although the addition of individual homologous mutations derived from the YE BE3 protein did not significantly increase the sequence specificity of the APO3A N57G double mutant, mutations to residues A71 and I96 greatly increased the homologous: non-homologous editing ratios at the three tested sites, from less than 5 to approximately 13 (Table 10). Fig.13 ).
[0177] Crucially, the exact nature of these mutations can differ in ways that depend on the mode of delivery. For example, delivering these agents via ribonucleoprotein (RNP) or encoded in mRNA can result in a shorter duration of protein in the cell. A shorter duration of base editor protein in the cell can result in a different mutation spectrum than longer-term delivery (e.g., via plasmid transfection). 45 As a result, it may be necessary to use engineered cytidine deaminase BEs that retain suboptimal sequence specificity when delivered via a plasmid, but retain optimal sequence specificity when delivered via a shorter-lived format, such as APO3AN57Q or K60D or Y130F BE3.
[0178] The engineered variant APO3A N57G BE3 also exhibited increased genome-wide fidelity at off-target sites compared to wild-type APO3A BE3 and BE3. We used plasmid DNA encoding APO3A BE3, APO3A N57G BE3, or BE3 together with expression of the well-characterized EMX1 gRNA ( Fig.14 ) or FANCF gRNA( Fig.15) were transiently transfected with a plasmid containing HF1 (Figure 5—figure supplement 1A). BE3 induced edits detectable by high-throughput sequencing at 16 of 25 previously identified off-target sites of EMX1 and 3 of 15 off-target sites of FANCF. In contrast, APO3A N57G BE3 induced edits at 6 of 25 sites of EMX1 and 0 of 15 sites of FANCF. At sites where APO3A N57G BE3 did induce off-target edits, it was at a greatly reduced frequency compared to BE3. Adding high-fidelity mutations from HF1 or Hypa SpCas9 to APO3A N57G BE3 reduced all off-target editing effects to below the detection threshold of the assay.
[0179] Finally, we sought to determine whether the APO3A N57G base editor could be used to more effectively correct the β-thalassemia mutation HBB-28(A>G). In the gRNA targeting this mutation on the antisense strand (CTGACTTcTATGCCCAGCCC (where the bold lowercase "c" is the target cytosine)), in addition to the target cytidine preceded by a 5'T at position -28, a second cytidine preceded by a 5'A (bystander cytidine) was present in the editing window. Mutations in bystander cytidines produce an independent β-thalassemia phenotype and should be avoided in any potential therapy for the HBB-28(A>G) mutation. We transiently transfected HEK293 cells carrying a lentiviral-integrated 200 base pair fragment encoding the HBB-28(A>G) mutation with a base editor encoding BE3 or APO3A N57GBE3 (and Fig.16 We harvested genomic DNA from cells after 72 hours and amplified the target sites using PCR, and sequenced the PCR products to examine the deamination frequencies of target and bystander cytidines by Illumina high-throughput sequencing.
[0180] We found that, while the BE3 and YE BE3 proteins edited target and bystander cytidines at roughly equivalent rates, APO3A N57G BE3 deaminated target cytidines approximately 15-fold more than bystander cytidines ( Fig.17). We then analyzed the frequency with which editing of the HBB-28 (A>G) locus with BE3 produced perfectly corrected alleles (i.e., alleles in which the -28 position had been edited but no other positions had been edited). BE3 produced perfectly edited alleles at a frequency of 0.5% of the total alleles sequenced. In contrast, editing with APO3A N57G BE3 produced perfectly edited alleles at a rate of 22% of the total alleles sequenced, 40-fold more than editing with BE3 ( Fig.18 ). We next investigated whether editing with APO3A N57G BE3 resulted in fewer off-target deamination events than BE3 when using the HBB-28(A>G) gRNA. BE3 induced detectable deamination at 3 of 8 off-target sites, whereas APO3A N57G BE3 induced editing at only 1 of 8 off-target sites ( Fig.19 ). Thus, the engineered APO3AN57GBE3 variant is able to more effectively correct the HBB-28 (A>G) pathogenic allele at the eight tested loci with fewer off-target effects, as compared to the BE3 protein or the prior art YE BE3 protein.
[0181] In additional experiments, human patient CD34+ HSPCs with HBB-28 (A>G) mutations harvested from donation were used. Purified A3A N57G BE3 protein was delivered to the cells along with guide RNA. After 5 days, gDNA was extracted and disease correction was evaluated by sequencing.
[0182] The mutations listed in Table 7 can be used alone or in any possible combination to increase the specificity of a deaminase protein or domain. The mutations listed in Table 8 are intended to alter targetable motif sequences and can be combined with any mutation in Table 7 to produce engineered deaminase proteins or domains with altered and increased substrate sequences. In addition, the mutations listed in Table 9 can be combined with any mutation listed in Table 7 or Table 8 to produce engineered deaminase proteins having altered specificity for the first or third nucleotide in a trinucleotide motif and increased specificity for its target motif relative to other possible deamination substrate motifs.
[0183] Table 7. Mutations that enhance the sequence specificity of cytidine deaminase proteins by affecting the protein: substrate interaction interface
[0184]
[0185] *Indicates proteins for which sufficient structural information is lacking.
[0186] Table 7 shows APOBEC orthologs with significant sequence and structural similarity for specificity engineering. In these cases, protein sequence alignment with APO3A was used to identify residues homologous to APO3A positions. Each of the six residue positions to be mutated is listed, along with one or more residues that are expected to increase the specificity of the deaminase domain for its typical substrate sequence or reengineered substrate sequence by reducing the excess binding energy between the deaminase protein and its ssDNA substrate.
[0187] Table 8. APOBEC orthologs with significant sequence and structural similarity for substrate sequence specificity reengineering (* indicates proteins lacking sufficient structural information)
[0188]
[0189] *Indicates proteins for which sufficient structural information is lacking.
[0190] In these cases, protein sequence alignments with APO3A were used to identify residues homologous to APO3A D131. For each dinucleotide motif, the position and identity of residue mutations expected to alter the sequence specificity of each protein are given. All position information refers to the wild-type protein sequence obtained from uniprot.org.
[0191] Table 9. APOBEC orthologs with significant sequence and structural similarity for substrate sequence specificity reengineering
[0192]
[0193] *Indicates proteins for which sufficient structural information is lacking.
[0194] In these cases, protein sequence alignment with APO3A was used to identify residues homologous to APO3A K30. For each trinucleotide motif, the position and identity of residue mutations expected to alter the sequence specificity of each protein are given. All position information refers to the wild-type protein sequence obtained from uniprot.org.
[0195] Table 10. Mutations that enhance the sequence specificity of cytidine deaminase proteins by affecting the kinetic rate and processivity of the enzyme
[0196]
[0197] References
[0198] 1.Komor,Alexis C.,Yongjoo B.Kim,Michael S.Packer,John A.Zuris,andDavid R.Liu."Programmable Editing of a Target Base in Genomic DNA withoutDouble-stranded DNA Cleavage."Nature 533.7603(2016):420-24.
[0199] 2.Yang,Luhan,Adrian W.Briggs,Wei Leong Chew,Prashant Mali,Marc Guell,John Aach,Daniel Bryan Goodman,David Cox,Yinan Kan,Emal Lesha,VenkataramananSoundararajan,Feng Zhang,and George Church."Engineering and OptimisingDeaminase Fusions for Genome Editing."Nature Communications 7(2016):13330.
[0200] 3.Jasin,Maria,and Rodney Rothstein."Repair of strand breaks byhomologous recombination."Cold Spring Harbor perspectives in biology 5.11(2013):a012740.
[0201] 4.Cone,Richard,Thomas Bonura,and E.C.Friedberg."Inhibitor of uracil-DNA glycosylase induced by bacteriophage PBS2.Purification and preliminarycharacterization."Journal of Biological Chemistry 255.21(1980):10354-10358.
[0202] 5.Kuscu,Cem,and Mazhar Adli."CRISPR-Cas9-AID Base Editor Is aPowerful Gain-of-function Screening Tool."Nature Methods 13.12(2016):983-84.
[0203] 6.Hess,Gaelen T.,Laure Frésard,Kyuho Han,Cameron H.Lee,Amy Li,KarleneA.Cimprich,Stephen B.Montgomery,and Michael C.Bassik."Directed EvolutionUsing DCas9-targeted Somatic Hypermutation in Mammalian Cells."Nature Methods13.12(2016):1036-042.
[0204] 7.Nishida,K.,T.Arazoe,N.Yachie,S.Banno,M.Kakimoto,M.Tabata,M.Mochizuki,A.Miyabe,M.Araki,K.Y.Hara,Z.Shimatani,and A.Kondo."TargetedNucleotide Editing Using Hybrid Prokaryotic and Vertebrate Adaptive ImmuneSystems."Science 353.6305(2016).
[0205] 8.Tsai,Shengdar Q.,Zongli Zheng,Nhu T.Nguyen,Matthew Liebers,VedV.Topkar,Vishal Thapar,Nicolas Wyvekens,Cyd Khayter,A.John Iafrate,Long P.Le,Martin J.Aryee,and J.Keith Joung."GUIDE-seq Enables Genome-wide Profiling ofOff-target Cleavage by CRISPR-Cas Nucleases."Nature Biotechnology 33.2(2014):187-97.
[0206] 9.Wu,Xuebing,David A.Scott,Andrea J.Kriz,Anthony C.Chiu,PatrickD.Hsu,Daniel B.Dadon,Albert W.Cheng,Alexandro E.Trevino,Silvana Konermann,Sidi Chen,Rudolf Jaenisch,Feng Zhang,and Phillip A.Sharp."Genome-wide Bindingof the CRISPR Endonuclease Cas9 in Mammalian Cells."Nature Biotechnology 32.7(2014):670-76.
[0207] 10.Kim,Y.Bill,Alexis C.Komor,Jonathan M.Levy,Michael S.Packer,KevinT.Zhao,and David R.Liu."Increasing the Genome-targeting Scope and Precisionof Base Editing with Engineered Cas9-cytidine Deaminase Fusions."NatureBiotechnology 35.4(2017):371-76.
[0208] 11.Byeon,In-Ja L.,Jinwoo Ahn,Mithun Mitra,Chang-Hyeock Byeon,KamilHercík,Jozef Hritz,Lisa M.Charlton,Judith G.Levin,and Angela M.Gronenborn."NMR Structure of Human Restriction Factor APOBEC3A Reveals Substrate Bindingand Enzyme Specificity."Nature Communications 4(2013):1890.
[0209] 12.Bransteitter,Ronda,Courtney Prochnow,and Xiaojiang S.Chen."TheCurrent Structural and Functional Understanding of APOBEC Deaminases."Cellular and Molecular Life Sciences 66.19(2009):3137-147.
[0210] 13.Mitra,Mithun,Dustin Singer,Yu Mano,Jozef Hritz,Gabriel Nam,RobertJ.Gorelick,In-Ja L.Byeon,Angela M.Gronenborn,Yasumasa Iwatani,and JudithG.Levin."Sequence and Structural Determinants of Human APOBEC3H Deaminase andAnti-HIV-1 Activities."Retrovirology 12.1(2015):3.
[0211] 14.Nair,S.,S.Sanchez-Martinez,X.Ji,and A.Rein."Biochemical andBiological Studies of Mouse APOBEC3."Journal of Virology 88.7(2014):3850-860.
[0212] 15.Langlois,Marc-André,et al."Mutational comparison of the single-domained APOBEC3C and double-domained APOBEC3F / G anti-retroviral cytidinedeaminases provides insight into their DNA target site specificities."Nucleicacids research 33.6(2005):1913-1923.
[0213] 16.Harris,Reuben S.,Svend K.Petersen-Mahrt,and Michael S.Neuberger."RNA Editing Enzyme APOBEC1 and Some of Its Homologs Can Act as DNA Mutators."Molecular Cell 10.5(2002):1247-253.
[0214] 17.Chen,Kuan-Ming,Elena Harjes,Phillip J.Gross,Amr Fahmy,Yongjian Lu,Keisuke Shindo,Reuben S.Harris,and Hiroshi Matsuo."Structure of the DNADeaminase Domain of the HIV-1 Restriction Factor APOBEC3G."Nature 452.7183(2008):116-19.
[0215] 18.Pham,Phuong,Samir A.Afif,Mayuko Shimoda,Kazuhiko Maeda,NobuoSakaguchi,Lars C.Pedersen,and Myron F.Goodman."Structural Analysis of theActivation-induced Deoxycytidine Deaminase Required in ImmunoglobulinDiversification."DNA Repair 43(2016):48-56.
[0216] 19.Shandilya,Shivender M.d.,Madhavi N.l.Nalam,Ellen A.Nalivaika,Phillip J.Gross,Johnathan C.Valesano,Keisuke Shindo,Ming Li,Mary Munson,William E.Royer,Elena Harjes,Takahide Kono,Hiroshi Matsuo,Reuben S.Harris,Mohan Somasundaran,and Celia A.Schiffer."Crystal Structure of the APOBEC3GCatalytic Domain Reveals Potential Oligomerization Interfaces."Structure 18.1(2010):28-38.
[0217] 20.Shi,Ke,Michael A.Carpenter,Kayo Kurahashi,Reuben S.Harris,andHideki Aihara."Crystal Structure of the DNA Deaminase APOBEC3B CatalyticDomain."Journal of Biological Chemistry 290.47(2015):28120-8130.
[0218] 21.Shi,Ke,Michael A.Carpenter,Surajit Banerjee,Nadine M.Shaban,KayoKurahashi,Daniel J.Salamango,Jennifer L.Mccann,Gabriel J.Starrett,JustinV.Duffy, Demir,Rommie E.Amaro,Daniel A.Harki,Reuben S.Harris,and HidekiAihara."Structural Basis for Targeted DNA Cytosine Deamination andMutagenesis by APOBEC3A and APOBEC3B."Nature Structural&Molecular Biology24.2(2016):131-39.
[0219] 22.Salter,Jason D.,Ryan P.Bennett,and Harold C.Smith."The APOBECProtein Family:United by Structure,Divergent in Function."Trends inBiochemical Sciences 41.7(2016):578-94.
[0220] 23.Holden LG,Prochnow C,Chang PY,Bransteitter R,Chelico L,Sen U,Stevens RC,Goodman MF,Chen XS(2008)Crystal structure of the anti-viralAPOBEC3G catalytic domain and functional implications.Nature 456:121–124.
[0221] 24.Logue,Eric C.,et al."A DNA sequence recognition loop on APOBEC3Acontrols substrate specificity."PloS one 9.5(2014):e97062.
[0222] 25.Kohli,R.M.,S.R.Abrams,K.S.Gajula,R.W.Maul,P.J.Gearhart,andJ.T.Stivers."A Portable Hot Spot Recognition Loop Transfers SequencePreferences from APOBEC Family Members to Activation-induced CytidineDeaminase."Journal of Biological Chemistry 284.34(2009):22898-2904.
[0223] 26.Kim,Daesik,Kayeong Lim,Sang-Tae Kim,Sun-Heui Yoon,Kyoungmi Kim,Seuk-Min Ryu,and Jin-Soo Kim."Genome-wide Target Specificities of CRISPR RNA-guided Programmable Deaminases."Nature Biotechnology(2017).
[0224] 27.Kleinstiver,Benjamin P.,Vikram Pattanayak,Michelle S.Prew,ShengdarQ.Tsai,Nhu T.Nguyen,Zongli Zheng,and J.Keith Joung."High-fidelity CRISPR–Cas9Nucleases with No Detectable Genome-wide Off-target Effects."Nature 529.7587(2016):490-95.
[0225] 28.Slaymaker,I.M.,L.Gao,B.Zetsche,D.A.Scott,W.X.Yan,and F.Zhang."Rationally Engineered Cas9 Nucleases with Improved Specificity."Science351.6268(2015):84-88.
[0226] 29.Dahlman,James E.,Omar O.Abudayyeh,Julia Joung,JonathanS.Gootenberg,Feng Zhang,and Silvana Konermann."Orthogonal Gene Knockout andActivation with a Catalytically Active Cas9 Nuclease."Nature Biotechnology33.11(2015):1159-161.
[0227] 30.Fu,Yanfang,et al."Improving CRISPR-Cas nuclease specificity usingtruncated guide RNAs."Nature biotechnology 32.3(2014):279-284.
[0228] 31.Boissel,S.,J.Jarjour,A.Astrakhan,A.Adey,A.Gouble,P.Duchateau,J.Shendure,B.L.Stoddard,M.T.Certo,D.Baker,and A.M.Scharenberg."MegaTALs:ARare-cleaving Nuclease Architecture for Therapeutic Genome Engineering."Nucleic Acids Research 42.4(2013):2591-601.
[0229] 32.Bolukbasi,Mehmet Fatih,Ankit Gupta,Sarah Oikemus,Alan G.Derr,Manuel Garber,Michael H.Brodsky,Lihua Julie Zhu,and Scot A.Wolfe."DNA-binding-domain Fusions Enhance the Targeting Range and Precision of Cas9."Nature Methods 12.12(2015):1150-156.
[0230] 33.Kleinstiver,Benjamin P.,et al."Broadening the targeting range ofStaphylococcus aureus CRISPR-Cas9 by modifying PAM recognition."Naturebiotechnology(2015).
[0231] 34.Ma,Enbo,et al."Single-stranded DNA cleavage by divergent CRISPR-Cas9 enzymes."Molecular cell 60.3(2015):398-407.
[0232] 35.Santos-Pereira,JoséM.,and Andrés Aguilera."R Loops:New Modulatorsof Genome Dynamics and Function."Nature Reviews Genetics 16.10(2015):583-97.
[0233] 36.Rebhandl,Stefan,Michael Huemer,Richard Greil,and RolandGeisberger."AID / APOBEC Deaminases and Cancer."Oncoscience 2(2015):320.
[0234] 37.Suspene,Rodolphe,et al."Recovery of APOBEC3-edited humanimmunodeficiency virus G→A hypermutants by differential DNA denaturationPCR."Journal of general virology 86.1(2005):125-129.
[0235] 38.Aynaud,Marie-Ming,et al."Human Tribbles 3 protects nuclear DNAfrom cytidine deamination by APOBEC3A."Journal of Biological Chemistry 287.46(2012):39182-39192.
[0236] 39.Shinohara,Masanobu,et al."APOBEC3B can impair genomic stability byinducing base substitutions in genomic DNA in human cells."Scientific reports2(2012):806.
[0237] 40.Holtz,Colleen M.,Holly A.Sadler,and Louis M.Mansky."APOBEC3Gcytosine deamination hotspots are defined by both sequence context andsingle-stranded DNA secondary structure."Nucleic acids research(2013):gkt246.
[0238] 41.Rebhandl,Stefan,Michael Huemer,Richard Greil,and RolandGeisberger."AID / APOBEC Deaminases and Cancer."Oncoscience 2(2015):320.
[0239] 42.Ear,Po Hien,and Stephen W.Michnick."A General Life-death SelectionStrategy for Dissecting Protein Functions."Nature Methods 6.11(2009):813-16.
[0240] 43.Luscombe,Nicholas M.,Roman A.Laskowski,and Janet M.Thornton."Aminoacid–base interactions:a three-dimensional analysis of protein–DNAinteractions at an atomic level."Nucleic acids research 29.13(2001):2860-2874.
[0241] 44.Kim,Y.Bill,et al."Increasing the genome-targeting scope andprecision of base editing with engineered Cas9-cytidine deaminase fusions."Nature Biotechnology 35.4(2017):371-376.
[0242] 45.Rees,Holly A.,et al."Improving the DNA specificity andapplicability of base editing through protein engineering and proteindelivery."Nature Communications 8(2017):ncomms15790.
[0243] 46.Kleinstiver,Benjamin P.,et al."Engineered CRISPR-Cas9 nucleaseswith altered PAM specificities."Nature 523.7561(2015):481-485.
[0244] 47.Kleinstiver,Benjamin P.,et al."Broadening the targeting range ofStaphylococcus aureus CRISPR-Cas9 by modifying PAM recognition."Naturebiotechnology 33.12(2015):1293-1298.
[0245] Other Implementations
[0246] It is to be understood that while the invention has been described in conjunction with its detailed description, the above description is intended to illustrate rather than limit the scope of the invention, which is defined by the scope of the appended claims. Other aspects, advantages and modifications are within the scope of the appended claims. Sequence Listing <110> The General Hospital Corporation <120> Base editors with improved precision and specificity <130> 29539-0337WO1 <140> PCT / US2018 / 034719 <141> 2018-05-25 <150> 62 / 511,296 <151> 2017-05-25 <150> 62 / 541,544 <151> 2017-08-04 <150> 62 / 622,676 <151> 2018-01-26 <160> 67 <170> PatentIn Version 3.5 <210> 1 <211> 12 <212> PRT <213> Artificial <220> <223> hAID fragment <400> 1 Gln Phe Lys Asn Val Arg Trp Ala Lys Gly Arg Arg 1 5 10 <210> 2 <211> 9 <212> PRT <213> Artificial <220> <223> Fragments of hAID soluble variant (hAIDv) <400> 2 Asn Phe Asn Asn Gly Ile Gly Arg His 1 5 <210> 3 <211> 9 <212> PRT <213> Artificial <220> <223> hAPOBEC3A fragment <400> 3 Asn Phe Asn Asn Gly Ile Gly Arg His 1 5 <210> 4 <211> 12 <212> PRT <213> Artificial <220> <223> hAPOBEC3C fragment <400> 4 Gln Phe Lys Asn Leu Trp Glu Ala Asn Asp Arg Asn 1 5 10 <210> 5 <211> 12 <212> PRT <213> Artificial <220> <223> hAPOBEC3F-catalytic domain fragment <400> 5 His Phe Lys Asn Leu Arg Lys Ala Tyr Gly Arg Asn 1 5 10 <210> 6 <211> 12 <212> PRT <213> Artificial <220> <223> hAPOBEC3G-catalytic domain fragment <400> 6 Asn Phe Asn Asn Glu Pro Trp Val Arg Gly Arg His 1 5 10 <210> 7 <211> 12 <212> PRT <213> Artificial <220> <223> mAPOBEC3-Fragment of the catalytic domain <400> 7 His Phe Lys Asn Leu Gly Tyr Ala Lys Gly Arg Lys 1 5 10 <210> 8 <211> 15 <212> PRT <213> Artificial <220> <223> hAPOBEC3H fragment <400> 8 Gln Phe Asn Asn Lys Arg Arg Leu Arg Arg Pro Tyr Tyr Pro Arg 1 5 10 15 <210> 9 <211> 9 <212> PRT <213> Artificial <220> <223> Fragments of rAPOBEC1 <400> 9 Phe Phe Asp Pro Arg Glu Leu Arg Lys 1 5 <210> 10 <211> 17 <212> PRT <213> Artificial <220> <223> hAID fragment <400> 10 Phe Thr Ala Arg Leu Tyr Phe Cys Glu Asp Arg Lys Ala Glu Pro Glu 1 5 10 15 Gly <210> 11 <211> 17 <212> PRT <213> Artificial <220> <223> Fragments of hAID soluble variant (hAIDv) <400> 11 Phe Thr Ala Arg Leu Tyr Phe Cys Glu Asp Arg Lys Ala Glu Pro Glu 1 5 10 15 Gly <210> 12 <211> 15 <212> PRT <213> Artificial <220> <223> hAPOBEC3A fragment <400> 12 Phe Ala Ala Arg Ile Tyr Asp Tyr Asp Pro Leu Tyr Lys Glu Ala 1 5 10 15 <210> 13 <211> 16 <212> PRT <213> Artificial <220> <223> hAPOBEC3C fragment <400> 13 Phe Thr Ala Arg Leu Tyr Tyr Phe Gln Tyr Pro Cys Tyr Gln Glu Gly 1 5 10 15 <210> 14 <211> 16 <212> PRT <213> Artificial <220> <223> hAPOBEC3F-catalytic domain fragment <400> 14 Phe Thr Ala Arg Leu Tyr Tyr Phe Trp Asp Thr Asp Tyr Gln Glu Gly 1 5 10 15 <210> 15 <211> 15 <212> PRT <213> Artificial <220> <223> hAPOBEC3G-catalytic domain fragment <400> 15 Phe Thr Ala Arg Ile Tyr Asp Asp Gln Gly Arg Cys Gln Glu Gly 1 5 10 15 <210> 16 <211> 16 <212> PRT <213> Artificial <220> <223> mAPOBEC3-Fragment of the catalytic domain <400> 16 Phe Ser Ser Arg Leu Tyr Asn Val Gln Asp Pro Glu Thr Gln Gln Asn 1 5 10 15 <210> 17 <211> 16 <212> PRT <213> Artificial <220> <223> hAPOBEC3H fragment <400> 17 Phe Ala Ser Arg Leu Tyr Tyr His Trp Cys Lys Pro Gln Gln Lys Gly 1 5 10 15 <210> 18 <211> 16 <212> PRT <213> Artificial <220> <223> Fragments of rAPOBEC1 <400> 18 Tyr Ile Ala Arg Leu Tyr His His Ala Asp Pro Arg Asn Arg Gln Gly 1 5 10 15 <210> 19 <211> twenty one <212> DNA <213> Artificial <220> <223> EGFP gRNA target sequence <400> 19 tcagctcgat gcggttcacc a 21 <210> 20 <211> twenty one <212> DNA <213> Artificial <220> <223> EGFP gRNA target sequence <400> 20 gcagaacacc cccatcggcg a 21 <210> twenty one <400> twenty one 000 <210> twenty two <211> twenty four <212> DNA <213> Artificial <220> <223> EGFP gRNA target sequence <400> twenty two tcagctcgat gcggttcacc aggg 24 <210> twenty three <211> 20 <212> DNA <213> Artificial <220> <223> AAVS1 target site 1 reference sequence <400> twenty three gactcaccca ggagtgcgtt 20 <210> twenty four <211> 20 <212> DNA <213> Artificial <220> <223> AAVS1 target site 2 reference sequence <400> twenty four gtccgactcg gccaggtcca 20 <210> 25 <211> 20 <212> DNA <213> Artificial <220> <223> AAVS1 target site 3 reference sequence <400> 25 gaccctcagc cgtgctgctc 20 <210> 26 <211> 20 <212> DNA <213> Artificial <220> <223> AAVS1 target site 4 reference sequence <400> 26 gctctcagcc tggagaccac 20 <210> 27 <211> 20 <212> DNA <213> Artificial <220> <223> AAVS1 target site 5 reference sequence <400> 27 gctgactcag agaccctgag 20 <210> 28 <211> 20 <212> DNA <213> Artificial <220> <223> AAVS1 target site 6 reference sequence <400> 28 ggggctcaac atcggaagag 20 <210> 29 <211> 20 <212> DNA <213> Artificial <220> <223> AAVS1 target site 7 reference sequence <400> 29 ggcactcggg ggcgagagga 20 <210> 30 <211> 20 <212> DNA <213> Artificial <220> <223> EMX1 target site 2 reference sequence <400> 30 gtattcacct gaaagtgtgc 20 <210> 31 <211> 20 <212> DNA <213> Artificial <220> <223> AAVS1 target site 8 reference sequence <400> 31 gagctcactg aacgctggca 20 <210> 32 <211> 20 <212> DNA <213> Artificial <220> <223> AAVS1 target site 9 reference sequence <400> 32 gctggctcag gttcaggaga 20 <210> 33 <211> 20 <212> DNA <213> Artificial <220> <223> FANCF target site 1 reference sequence <400> 33 ggaatccctt ctgcagcacc 20 <210> 34 <211> 20 <212> DNA <213> Artificial <220> <223> EMX1 target site 1 reference sequence <400> 34 gagtccgagc agaagaagaa 20 <210> 35 <211> 20 <212> DNA <213> Artificial sequence <220> <223> AAVS1 target site 6 reference sequence <400> 35 ggggctcaac atcggaagag 20 <210> 36 <211> 20 <212> DNA <213> Artificial <220> <223> AAVS1 target site 3 reference sequence <400> 36 gaccctcagc cgtgctgctc 20 <210> 37 <211> 20 <212> DNA <213> Artificial <220> <223> AAVS1 target site 7 reference sequence <400> 37 ggcactcggg ggcgagagga 20 <210> 38 <211> 20 <212> DNA <213> Artificial <220> <223> Potential HBB allele products <400> 38 ctgaatttta tgcccagccc 20 <210> 39 <211> 20 <212> DNA <213> Artificial <220> <223> Potential HBB allele products <400> 39 ctgagtttta tgcccagccc 20 <210> 40 <211> 20 <212> DNA <213> Artificial <220> <223> Potential HBB allele products <400> 40 ctgattttta tgcccagccc 20 <210> 41 <211> 20 <212> DNA <213> Artificial <220> <223> Potential HBB allele products <400> 41 ctgacttgta tgcccagccc 20 <210> 42 <211> 20 <212> DNA <213> Artificial <220> <223> Potential HBB allele products <400> 42 ctgactttta tgcccagccc 20 <210> 43 <211> 20 <212> DNA <213> Artificial <220> <223> HBB target site reference sequence <400> 43 ctgacttcta tgcccagccc 20 <210> 44 <211> twenty three <212> DNA <213> Artificial <220> <223> HBB target site reference sequence <220> <221> misc_feature <222> (21)..(21) <223> n is a, c, g, or t <400> 44 ctgacttcta tgcccagccc ngg 23 <210> 45 <211> 83 <212> PRT <213> Artificial <220> <223> Uracil glycosylase inhibitors (UGI) <400> 45 Thr Asn Leu Ser Asp Ile Ile Glu Lys Glu Thr Gly Lys Gln Leu Val 1 5 10 15 Ile Gln Glu Ser Ile Leu Met Leu Pro Glu Glu Val Glu Glu Val Ile 20 25 30 Gly Asn Lys Pro Glu Ser Asp Ile Leu Val His Thr Ala Tyr Asp Glu 35 40 45 Ser Thr Asp Glu Asn Val Met Leu Leu Thr Ser Asp Ala Pro Glu Tyr 50 55 60 Lys Pro Trp Ala Leu Val Ile Gln Asp Ser Asn Gly Glu Asn Lys Ile 65 70 75 80 Lys Met Leu <210> 46 <211> 4 <212> PRT <213> Artificial <220> <223> Adapter sequence <400> 46 Gly Gly Gly Ser 1 <210> 47 <211> 5 <212> PRT <213> Artificial <220> <223> Adapter sequence <400> 47 Gly Gly Gly Gly Ser 1 5 <210> 48 <211> 7 <212> PRT <213> Artificial <220> <223> SV40 Large T Antigen NLS <400> 48 Pro Lys Lys Lys Arg Arg Val 1 5 <210> 49 <211> 15 <212> PRT <213> Artificial <220> <223> Nucleoplasmin NLS <400> 49 Lys Arg Pro Ala Ala Thr Lys Lys Ala Gly Gln Ala Lys Lys Lys 1 5 10 15 <210> 50 <211> 1710 <212> PRT <213> Artificial <220> <223> rAPOBEC1-XTEN L8-nCas9-UGI-SV40 NLS <400> 50 Met Ser Ser Glu Thr Gly Pro Val Ala Val Asp Pro Thr Leu Arg Arg 1 5 10 15 Arg Ile Glu Pro His Glu Phe Glu Val Phe Phe Asp Pro Arg Glu Leu 20 25 30 Arg Lys Glu Thr Cys Leu Leu Tyr Glu Ile Asn Trp Gly Gly Arg His 35 40 45 Ser Ile Trp Arg His Thr Ser Gln Asn Thr Asn Lys His Val Glu Val 50 55 60 Asn Phe Ile Glu Lys Phe Thr Thr Glu Arg Tyr Phe Cys Pro Asn Thr 65 70 75 80 Arg Cys Ser Ile Thr Trp Phe Leu Ser Trp Ser Pro Cys Gly Glu Cys 85 90 95 Ser Arg Ala Ile Thr Glu Phe Leu Ser Arg Tyr Pro His Val Thr Leu 100 105 110 Phe Ile Tyr Ile Ala Arg Leu Tyr His His Ala Asp Pro Arg Asn Arg 115 120 125 Gln Gly Leu Arg Asp Leu Ile Ser Ser Gly Val Thr Ile Gln Ile Met 130 135 140 Thr Glu Gln Glu Ser Gly Tyr Cys Trp Arg Asn Phe Val Asn Tyr Ser 145 150 155 160 Pro Ser Asn Glu Ala His Trp Pro Arg Tyr Pro His Leu Trp Val Arg 165 170 175 Leu Tyr Val Leu Glu Leu Tyr Cys Ile Ile Leu Gly Leu Pro Pro Cys 180 185 190 Leu Asn Ile Leu Arg Arg Lys Gln Pro Gln Leu Thr Phe Phe Thr Ile 195 200 205 Ala Leu Gln Ser Cys His Tyr Gln Arg Leu Pro Pro His Ile Leu Trp 210 215 220 Ala Thr Gly Leu Lys Ser Gly Ser Glu Thr Pro Gly Thr Ser Glu Ser 225 230 235 240 Ala Thr Pro Glu Ser Asp Lys Lys Tyr Ser Ile Gly Leu Ala Ile Gly 245 250 255 Thr Asn Ser Val Gly Trp Ala Val Ile Thr Asp Glu Tyr Lys Val Pro 260 265 270 Ser Lys Lys Phe Lys Val Leu Gly Asn Thr Asp Arg His Ser Ile Lys 275 280 285 Lys Asn Leu Ile Gly Ala Leu Leu Phe Asp Ser Gly Glu Thr Ala Glu 290 295 300 Ala Thr Arg Leu Lys Arg Thr Ala Arg Arg Arg Tyr Thr Arg Arg Lys 305 310 315 320 Asn Arg Ile Cys Tyr Leu Gln Glu Ile Phe Ser Asn Glu Met Ala Lys 325 330 335 Val Asp Asp Ser Phe Phe His Arg Leu Glu Glu Ser Phe Leu Val Glu 340 345 350 Glu Asp Lys Lys His Glu Arg His Pro Ile Phe Gly Asn Ile Val Asp 355 360 365 Glu Val Ala Tyr His Glu Lys Tyr Pro Thr Ile Tyr His Leu Arg Lys 370 375 380 Lys Leu Val Asp Ser Thr Asp Lys Ala Asp Leu Arg Leu Ile Tyr Leu 385 390 395 400 Ala Leu Ala His Met Ile Lys Phe Arg Gly His Phe Leu Ile Glu Gly 405 410 415 Asp Leu Asn Pro Asp Asn Ser Asp Val Asp Lys Leu Phe Ile Gln Leu 420 425 430 Val Gln Thr Tyr Asn Gln Leu Phe Glu Glu Asn Pro Ile Asn Ala Ser 435 440 445 Gly Val Asp Ala Lys Ala Ile Leu Ser Ala Arg Leu Ser Lys Ser Arg 450 455 460 Arg Leu Glu Asn Leu Ile Ala Gln Leu Pro Gly Glu Lys Lys Asn Gly 465 470 475 480 Leu Phe Gly Asn Leu Ile Ala Leu Ser Leu Gly Leu Thr Pro Asn Phe 485 490 495 Lys Ser Asn Phe Asp Leu Ala Glu Asp Ala Lys Leu Gln Leu Ser Lys 500 505 510 Asp Thr Tyr Asp Asp Asp Leu Asp Asn Leu Leu Ala Gln Ile Gly Asp 515 520 525 Gln Tyr Ala Asp Leu Phe Leu Ala Ala Lys Asn Leu Ser Asp Ala Ile 530 535 540 Leu Leu Ser Asp Ile Leu Arg Val Asn Thr Glu Ile Thr Lys Ala Pro 545 550 555 560 Leu Ser Ala Ser Met Ile Lys Arg Tyr Asp Glu His His Gln Asp Leu 565 570 575 Thr Leu Leu Lys Ala Leu Val Arg Gln Gln Leu Pro Glu Lys Tyr Lys 580 585 590 Glu Ile Phe Phe Asp Gln Ser Lys Asn Gly Tyr Ala Gly Tyr Ile Asp 595 600 605 Gly Gly Ala Ser Gln Glu Glu Phe Tyr Lys Phe Ile Lys Pro Ile Leu 610 615 620 Glu Lys Met Asp Gly Thr Glu Glu Leu Leu Val Lys Leu Asn Arg Glu 625 630 635 640 Asp Leu Leu Arg Lys Gln Arg Thr Phe Asp Asn Gly Ser Ile Pro His 645 650 655 Gln Ile His Leu Gly Glu Leu His Ala Ile Leu Arg Arg Gln Glu Asp 660 665 670 Phe Tyr Pro Phe Leu Lys Asp Asn Arg Glu Lys Ile Glu Lys Ile Leu 675 680 685 Thr Phe Arg Ile Pro Tyr Tyr Val Gly Pro Leu Ala Arg Gly Asn Ser 690 695 700 Arg Phe Ala Trp Met Thr Arg Lys Ser Glu Glu Thr Ile Thr Pro Trp 705 710 715 720 Asn Phe Glu Glu Val Val Asp Lys Gly Ala Ser Ala Gln Ser Phe Ile 725 730 735 Glu Arg Met Thr Asn Phe Asp Lys Asn Leu Pro Asn Glu Lys Val Leu 740 745 750 Pro Lys His Ser Leu Leu Tyr Glu Tyr Phe Thr Val Tyr Asn Glu Leu 755 760 765 Thr Lys Val Lys Tyr Val Thr Glu Gly Met Arg Lys Pro Ala Phe Leu 770 775 780 Ser Gly Glu Gln Lys Lys Ala Ile Val Asp Leu Leu Phe Lys Thr Asn 785 790 795 800 Arg Lys Val Thr Val Lys Gln Leu Lys Glu Asp Tyr Phe Lys Lys Ile 805 810 815 Glu Cys Phe Asp Ser Val Glu Ile Ser Gly Val Glu Asp Arg Phe Asn 820 825 830 Ala Ser Leu Gly Thr Tyr His Asp Leu Leu Lys Ile Ile Lys Asp Lys 835 840 845 Asp Phe Leu Asp Asn Glu Glu Asn Glu Asp Ile Leu Glu Asp Ile Val 850 855 860 Leu Thr Leu Thr Leu Phe Glu Asp Arg Glu Met Ile Glu Glu Arg Leu 865 870 875 880 Lys Thr Tyr Ala His Leu Phe Asp Asp Lys Val Met Lys Gln Leu Lys 885 890 895 Arg Arg Arg Tyr Thr Gly Trp Gly Arg Leu Ser Arg Lys Leu Ile Asn 900 905 910 Gly Ile Arg Asp Lys Gln Ser Gly Lys Thr Ile Leu Asp Phe Leu Lys 915 920 925 Ser Asp Gly Phe Ala Asn Arg Asn Phe Met Gln Leu Ile His Asp Asp 930 935 940 Ser Leu Thr Phe Lys Glu Asp Ile Gln Lys Ala Gln Val Ser Gly Gln 945 950 955 960 Gly Asp Ser Leu His Glu His Ile Ala Asn Leu Ala Gly Ser Pro Ala 965 970 975 Ile Lys Lys Gly Ile Leu Gln Thr Val Lys Val Val Asp Glu Leu Val 980 985 990 Lys Val Met Gly Arg His Lys Pro Glu Asn Ile Val Ile Glu Met Ala 995 1000 1005 Arg Glu Asn Gln Thr Thr Gln Lys Gly Gln Lys Asn Ser Arg Glu 1010 1015 1020 Arg Met Lys Arg Ile Glu Glu Gly Ile Lys Glu Leu Gly Ser Gln 1025 1030 1035 Ile Leu Lys Glu His Pro Val Glu Asn Thr Gln Leu Gln Asn Glu 1040 1045 1050 Lys Leu Tyr Leu Tyr Tyr Leu Gln Asn Gly Arg Asp Met Tyr Val 1055 1060 1065 Asp Gln Glu Leu Asp Ile Asn Arg Leu Ser Asp Tyr Asp Val Asp 1070 1075 1080 His Ile Val Pro Gln Ser Phe Leu Lys Asp Asp Ser Ile Asp Asn 1085 1090 1095 Lys Val Leu Thr Arg Ser Asp Lys Asn Arg Gly Lys Ser Asp Asn 1100 1105 1110 Val Pro Ser Glu Glu Val Val Lys Lys Met Lys Asn Tyr Trp Arg 1115 1120 1125 Gln Leu Leu Asn Ala Lys Leu Ile Thr Gln Arg Lys Phe Asp Asn 1130 1135 1140 Leu Thr Lys Ala Glu Arg Gly Gly Leu Ser Glu Leu Asp Lys Ala 1145 1150 1155 Gly Phe With Lys Arg Gln Leu Val Glu Thr Arg Gln With Thr Lys 1160 1165 1170 His Val Only Gln Ile Leu Asp Ser Arg Met Asn Thr Lys Tyr Asp 1175 1180 1185 Glu Asn Asp Lys With Arg Glu Val Lys Val With Thr Lys 1190 1195 1200 Ser Lys Leu Val Ser Asp Phe Arg Lys Asp Phe Gln Phe Tyr Lys 1205 1210 1215 Val Arg Glu Ile Asn Asn Tyr His Ala His Asp Ala Tyr Leu 1220 1225 1230 Asn Ala Val Gly Thr Ala Leu Ile Lys Lys Tyr Pro Lys Leu 1235 1240 1245 Glu Ser Glu Phe Val Tyr Gly Asp Tyr Lys Val Tyr Asp Val Arg 1250 1255 1260 Lys Met Ile Ala Lys Ser Glu Gln Glu Ile Gly Lys Ala Thr Ala 1265 1270 1275 Lys Tyr Phe Phe Tyr Ser Asn Ile Met Asn Phe Phe Lys Thr Glu 1280 1285 1290 Ile Thr Leu Ala Asn Gly Glu Ile Arg Lys Arg Pro Leu Ile Glu 1295 1300 1305 Thr Asn Gly Glu Thr Gly Glu Ile Val Trp Asp Lys Gly Arg Asp 1310 1315 1320 Phe Ala Thr Val Arg Lys Val Leu Ser Met Pro Gln Val Asn Ile 1325 1330 1335 Val Lys Lys Thr Glu Val Gln Thr Gly Gly Phe Ser Lys Glu Ser 1340 1345 1350 Ile Leu Pro Lys Arg Asn Ser Asp Lys Leu Ile Ala Arg Lys Lys 1355 1360 1365 Asp Trp Asp Pro Lys Lys Tyr Gly Gly Phe Asp Ser Pro Thr Val 1370 1375 1380 Ala Tyr Ser Val Leu Val Val Ala Lys Val Glu Lys Gly Lys Ser 1385 1390 1395 Lys Lys Leu Lys Ser Val Lys Glu Leu Leu Gly Ile Thr Ile Met 1400 1405 1410 Glu Arg Ser Ser Phe Glu Lys Asn Pro Ile Asp Phe Leu Glu Ala 1415 1420 1425 Lys Gly Tyr Lys Glu Val Lys Lys Asp Leu Ile Ile Lys Leu Pro 1430 1435 1440 Lys Tyr Ser Leu Phe Glu Leu Glu Asn Gly Arg Lys Arg Met Leu 1445 1450 1455 Ala Ser Ala Gly Glu Leu Gln Lys Gly Asn Glu Leu Ala Leu Pro 1460 1465 1470 Ser Lys Tyr Val Asn Phe Leu Tyr Leu Ala Ser His Tyr Glu Lys 1475 1480 1485 Leu Lys Gly Ser Pro Glu Asp Asn Glu Gln Lys Gln Leu Phe Val 1490 1495 1500 Glu Gln His Lys His Tyr Leu Asp Glu Ile Ile Glu Gln Ile Ser 1505 1510 1515 Glu Phe Ser Lys Arg Val Ile Leu Ala Asp Ala Asn Leu Asp Lys 1520 1525 1530 Val Leu Ser Ala Tyr Asn Lys His Arg Asp Lys Pro Ile Arg Glu 1535 1540 1545 Gln Ala Glu Asn Ile Ile His Leu Phe Thr Leu Thr Asn Leu Gly 1550 1555 1560 Ala Pro Ala Ala Phe Lys Tyr Phe Asp Thr Thr Ile Asp Arg Lys 1565 1570 1575 Arg Tyr Thr Ser Thr Lys Glu Val Leu Asp Ala Thr Leu Ile His 1580 1585 1590 Gln Ser Ile Thr Gly Leu Tyr Glu Thr Arg Ile Asp Leu Ser Gln 1595 1600 1605 Leu Gly Gly Asp Ser Gly Gly Ser Thr Asn Leu Ser Asp Ile Ile 1610 1615 1620 Glu Lys Glu Thr Gly Lys Gln Leu Val Ile Gln Glu Ser Ile Leu 1625 1630 1635 Met Leu Pro Glu Glu Val Glu Glu Val Ile Gly Asn Lys Pro Glu 1640 1645 1650 Ser Asp Ile Leu Val His Thr Ala Tyr Asp Glu Ser Thr Asp Glu 1655 1660 1665 Asn Val Met Leu Leu Thr Ser Asp Ala Pro Glu Tyr Lys Pro Trp 1670 1675 1680 Ala Leu Val Ile Gln Asp Ser Asn Gly Glu Asn Lys Ile Lys Met 1685 1690 1695 Leu Ser Gly Gly Ser Pro Lys Lys Lys Arg Lys Val 1700 1705 1710 <210> 51 <211> 198 <212> PRT <213> Homo sapiens <400> 51 Met Asp Ser Leu Leu Met Asn Arg Arg Lys Phe Leu Tyr Gln Phe Lys 1 5 10 15 Asn Val Arg Trp Ala Lys Gly Arg Arg Glu Thr Tyr Leu Cys Tyr Val 20 25 30 Val Lys Arg Arg Asp Ser Ala Thr Ser Phe Ser Leu Asp Phe Gly Tyr 35 40 45 Leu Arg Asn Lys Asn Gly Cys His Val Glu Leu Leu Phe Leu Arg Tyr 50 55 60 Ile Ser Asp Trp Asp Leu Asp Pro Gly Arg Cys Tyr Arg Val Thr Trp 65 70 75 80 Phe Thr Ser Trp Ser Pro Cys Tyr Asp Cys Ala Arg His Val Ala Asp 85 90 95 Phe Leu Arg Gly Asn Pro Asn Leu Ser Leu Arg Ile Phe Thr Ala Arg 100 105 110 Leu Tyr Phe Cys Glu Asp Arg Lys Ala Glu Pro Glu Gly Leu Arg Arg 115 120 125 Leu His Arg Ala Gly Val Gln Ile Ala Ile Met Thr Phe Lys Asp Tyr 130 135 140 Phe Tyr Cys Trp Asn Thr Phe Val Glu Asn His Glu Arg Thr Phe Lys 145 150 155 160 Ala Trp Glu Gly Leu His Glu Asn Ser Val Arg Leu Ser Arg Gln Leu 165 170 175 Arg Arg Ile Leu Leu Pro Leu Tyr Glu Val Asp Asp Leu Arg Asp Ala 180 185 190 Phe Arg Thr Leu Gly Leu 195 <210> 52 <211> 190 <212> PRT <213> Artificial <220> <223> Solubility variant of hAIDv lacking the N-terminal RNA binding region <400> 52 Met Asp Pro His Ile Phe Thr Ser Asn Phe Asn Asn Gly Ile Gly Arg 1 5 10 15 His Lys Thr Tyr Leu Cys Tyr Glu Val Glu Arg Leu Asp Ser Ala Thr 20 25 30 Ser Phe Ser Leu Asp Phe Gly Tyr Leu Arg Asn Lys Asn Gly Cys His 35 40 45 Val Glu Leu Leu Phe Leu Arg Tyr Ile Ser Asp Trp Asp Leu Asp Pro 50 55 60 Gly Arg Cys Tyr Arg Val Thr Trp Phe Thr Ser Trp Ser Pro Cys Tyr 65 70 75 80 Asp Cys Ala Arg His Val Ala Asp Phe Leu Arg Gly Asn Pro Asn Leu 85 90 95 Ser Leu Arg Ile Phe Thr Ala Arg Leu Tyr Phe Cys Glu Asp Arg Lys 100 105 110 Ala Glu Pro Glu Gly Leu Arg Arg Leu His Arg Ala Gly Val Gln Ile 115 120 125 Ala Ile Met Thr Phe Lys Asp Tyr Phe Tyr Cys Trp Asn Thr Phe Val 130 135 140 Glu Asn His Glu Arg Thr Phe Lys Ala Trp Glu Gly Leu His Glu Asn 145 150 155 160 Ser Val Arg Leu Ser Arg Gln Leu Arg Arg Ile Leu Leu Pro Leu Tyr 165 170 175 Glu Val Asp Asp Leu Arg Asp Ala Phe Arg Thr Leu Gly Leu 180 185 190 <210> 53 <211> 175 <212> PRT <213> Artificial <220> <223> Solubility variant of hAIDv lacking the N-terminal RNA binding region and the C-terminal poorly structured region <400> 53 Met Asp Pro His Ile Phe Thr Ser Asn Phe Asn Asn Gly Ile Gly Arg 1 5 10 15 His Lys Thr Tyr Leu Cys Tyr Glu Val Glu Arg Leu Asp Ser Ala Thr 20 25 30 Ser Phe Ser Leu Asp Phe Gly Tyr Leu Arg Asn Lys Asn Gly Cys His 35 40 45 Val Glu Leu Leu Phe Leu Arg Tyr Ile Ser Asp Trp Asp Leu Asp Pro 50 55 60 Gly Arg Cys Tyr Arg Val Thr Trp Phe Thr Ser Trp Ser Pro Cys Tyr 65 70 75 80 Asp Cys Ala Arg His Val Ala Asp Phe Leu Arg Gly Asn Pro Asn Leu 85 90 95 Ser Leu Arg Ile Phe Thr Ala Arg Leu Tyr Phe Cys Glu Asp Arg Lys 100 105 110 Ala Glu Pro Glu Gly Leu Arg Arg Leu His Arg Ala Gly Val Gln Ile 115 120 125 Ala Ile Met Thr Phe Lys Asp Tyr Phe Tyr Cys Trp Asn Thr Phe Val 130 135 140 Glu Asn His Glu Arg Thr Phe Lys Ala Trp Glu Gly Leu His Glu Asn 145 150 155 160 Ser Val Arg Leu Ser Arg Gln Leu Arg Arg Ile Leu Leu Pro Leu 165 170 175 <210> 54 <211> 229 <212> PRT <213> Rattus norvegicus <400> 54 Met Ser Ser Glu Thr Gly Pro Val Ala Val Asp Pro Thr Leu Arg Arg 1 5 10 15 Arg Ile Glu Pro His Glu Phe Glu Val Phe Phe Asp Pro Arg Glu Leu 20 25 30 Arg Lys Glu Thr Cys Leu Leu Tyr Glu Ile Asn Trp Gly Gly Arg His 35 40 45 Ser Ile Trp Arg His Thr Ser Gln Asn Thr Asn Lys His Val Glu Val 50 55 60 Asn Phe Ile Glu Lys Phe Thr Thr Glu Arg Tyr Phe Cys Pro Asn Thr 65 70 75 80 Arg Cys Ser Ile Thr Trp Phe Leu Ser Trp Ser Pro Cys Gly Glu Cys 85 90 95 Ser Arg Ala Ile Thr Glu Phe Leu Ser Arg Tyr Pro His Val Thr Leu 100 105 110 Phe Ile Tyr Ile Ala Arg Leu Tyr His His Ala Asp Pro Arg Asn Arg 115 120 125 Gln Gly Leu Arg Asp Leu Ile Ser Ser Gly Val Thr Ile Gln Ile Met 130 135 140 Thr Glu Gln Glu Ser Gly Tyr Cys Trp Arg Asn Phe Val Asn Tyr Ser 145 150 155 160 Pro Ser Asn Glu Ala His Trp Pro Arg Tyr Pro His Leu Trp Val Arg 165 170 175 Leu Tyr Val Leu Glu Leu Tyr Cys Ile Ile Leu Gly Leu Pro Pro Cys 180 185 190 Leu Asn Ile Leu Arg Arg Lys Gln Pro Gln Leu Thr Phe Phe Thr Ile 195 200 205 Ala Leu Gln Ser Cys His Tyr Gln Arg Leu Pro Pro His Ile Leu Trp 210 215 220 Ala Thr Gly Leu Lys 225 <210> 55 <211> 397 <212> PRT <213> Mus musculus <400> 55 Met Gly Pro Phe Cys Leu Gly Cys Ser His Arg Lys Cys Tyr Ser Pro 1 5 10 15 Ile Arg Asn Leu Ile Ser Gln Glu Thr Phe Lys Phe His Phe Lys Asn 20 25 30 Leu Gly Tyr Ala Lys Gly Arg Lys Asp Thr Phe Leu Cys Tyr Glu Val 35 40 45 Thr Arg Lys Asp Cys Asp Ser Pro Val Ser Leu His His Gly Val Phe 50 55 60 Lys Asn Lys Asp Asn Ile His Ala Glu Ile Cys Phe Leu Tyr Trp Phe 65 70 75 80 His Asp Lys Val Leu Lys Val Leu Ser Arg Glu Glu Phe Lys Ile 85 90 95 Thr Trp Tyr Met Ser Trp Ser Pro Cys Phe Glu Cys Ala Glu Gln Ile 100 105 110 Val Arg Phe Leu Ala Thr His His Asn Leu Ser Leu Asp Ile Phe Ser 115 120 125 Ser Arg Leu Tyr Asn Val Gln Asp Pro Glu Thr Gln Asn Leu Cys 130 135 140 Arg Leu Val Gln Glu Gly Ala Gln Val Ala Ala Met Asp Leu Tyr Glu 145 150 155 160 Phe Lys Cys Trp Lys Lys Phe Val Asp Gly Gly Arg Arg Phe 165 170 175 Arg Pro Trp Lys Arg Leu Leu Thr Asn Phe Arg Tyr Gln Asp Ser Lys 180 185 190 Leu Gln Glu Ile Leu Arg Arg Met Asp Pro Leu Ser Glu Glu Glu Phe 195 200 205 Tyr Ser Gln Phe Tyr Asn Gln Arg Val Lys His Leu Cys Tyr Tyr His 210 215 220 Arg Met Lys Pro Tyr Leu Cys Tyr Gln Leu Glu Gln Phe Asn Gly Gln 225 230 235 240 Ala Pro Leu Lys Gly Cys Leu Leu Ser Glu Lys Gly Lys Gln His Ala 245 250 255 Glu Ile Leu Phe Leu Asp Lys Ile Arg Ser Met Glu Leu Ser Gln Val 260 265 270 Thr Ile Thr Cys Tyr Leu Thr Trp Ser Pro Cys Pro Asn Cys Ala Trp 275 280 285 Gln Leu Ala Ala Phe Lys Arg Asp Arg Pro Asp Leu Ile Leu His Ile 290 295 300 Tyr Thr Ser Arg Leu Tyr Phe His Trp Lys Arg Pro Phe Gln Lys Gly 305 310 315 320 Leu Cys Ser Leu Trp Gln Ser Gly Ile Leu Val Asp Val Met Asp Leu 325 330 335 Pro Gln Phe Thr Asp Cys Trp Thr Asn Phe Val Asn Pro Lys Arg Pro 340 345 350 Phe Arg Pro Trp Lys Gly Leu Glu Ile Ile Ser Arg Arg Thr Gln Arg 355 360 365 Arg Leu Arg Arg Ile Lys Glu Ser Trp Gly Leu Gln Asp Leu Val Asn 370 375 380 Asp Phe Gly Asn Leu Gln Leu Gly Pro Pro Met Ser Asn 385 390 395 <210> 56 <211> 199 <212> PRT <213> Artificial <220> <223> mAPOBEC3 Catalytic Domain <400> 56 Met Gly Pro Phe Cys Leu Gly Cys Ser His Arg Lys Cys Tyr Ser Pro 1 5 10 15 Ile Arg Asn Leu Ile Ser Gln Glu Thr Phe Lys Phe His Phe Lys Asn 20 25 30 Leu Gly Tyr Ala Lys Gly Arg Lys Asp Thr Phe Leu Cys Tyr Glu Val 35 40 45 Thr Arg Lys Asp Cys Asp Ser Pro Val Ser Leu His His Gly Val Phe 50 55 60 Lys Asn Lys Asp Asn Ile His Ala Glu Ile Cys Phe Leu Tyr Trp Phe 65 70 75 80 His Asp Lys Val Leu Lys Val Leu Ser Pro Arg Glu Glu Phe Lys Ile 85 90 95 Thr Trp Tyr Met Ser Trp Ser Pro Cys Phe Glu Cys Ala Glu Gln Ile 100 105 110 Val Arg Phe Leu Ala Thr His His Asn Leu Ser Leu Asp Ile Phe Ser 115 120 125 Ser Arg Leu Tyr Asn Val Gln Asp Pro Glu Thr Gln Gln Asn Leu Cys 130 135 140 Arg Leu Val Gln Glu Gly Ala Gln Val Ala Ala Met Asp Leu Tyr Glu 145 150 155 160 Phe Lys Lys Cys Trp Lys Lys Phe Val Asp Asn Gly Gly Arg Arg Phe 165 170 175 Arg Pro Trp Lys Arg Leu Leu Thr Asn Phe Arg Tyr Gln Asp Ser Lys 180 185 190 Leu Gln Glu Ile Leu Arg Arg 195 <210> 57 <211> 199 <212> PRT <213> Homo sapiens <400> 57 Met Glu Ala Ser Pro Ala Ser Gly Pro Arg His Leu Met Asp Pro His 1 5 10 15 Ile Phe Thr Ser Asn Phe Asn Asn Gly Ile Gly Arg His Lys Thr Tyr 20 25 30 Leu Cys Tyr Glu Val Glu Arg Leu Asp Asn Gly Thr Ser Val Lys Met 35 40 45 Asp Gln His Arg Gly Phe Leu His Asn Gln Ala Lys Asn Leu Leu Cys 50 55 60 Gly Phe Tyr Gly Arg His Ala Glu Leu Arg Phe Leu Asp Leu Val Pro 65 70 75 80 Ser Leu Gln Leu Asp Pro Ala Gln Ile Tyr Arg Val Thr Trp Phe Ile 85 90 95 Ser Trp Ser Pro Cys Phe Ser Trp Gly Cys Ala Gly Glu Val Arg Ala 100 105 110 Phe Leu Gln Glu Asn Thr His Val Arg Leu Arg Ile Phe Ala Ala Arg 115 120 125 Ile Tyr Asp Tyr Asp Pro Leu Tyr Lys Glu Ala Leu Gln Met Leu Arg 130 135 140 Asp Ala Gly Ala Gln Val Ser Ile Met Thr Tyr Asp Glu Phe Lys His 145 150 155 160 Cys Trp Asp Thr Phe Val Asp His Gln Gly Cys Pro Phe Gln Pro Trp 165 170 175 Asp Gly Leu Asp Glu His Ser Gln Ala Leu Ser Gly Arg Leu Arg Ala 180 185 190 Ile Leu Gln Asn Gln Gly Asn 195 <210> 58 <211> 384 <212> PRT <213> Homo sapiens <400> 58 Met Lys Pro His Phe Arg Asn Thr Val Glu Arg Met Tyr Arg Asp Thr 1 5 10 15 Phe Ser Tyr Asn Phe Tyr Asn Arg Pro Ile Leu Ser Arg Arg Asn Thr 20 25 30 Val Trp Leu Cys Tyr Glu Val Lys Thr Lys Gly Pro Ser Arg Pro Pro 35 40 45 Leu Asp Ala Lys Ile Phe Arg Gly Gln Val Tyr Ser Glu Leu Lys Tyr 50 55 60 His Pro Glu Met Arg Phe Phe His Trp Phe Ser Lys Trp Arg Lys Leu 65 70 75 80 His Arg Asp Gln Glu Tyr Glu Val Thr Trp Tyr Ile Ser Trp Ser Pro 85 90 95 Cys Thr Lys Cys Thr Arg Asp Met Ala Thr Phe Leu Ala Glu Asp Pro 100 105 110 Lys Val Thr Leu Thr Ile Phe Val Ala Arg Leu Tyr Tyr Phe Trp Asp 115 120 125 Pro Asp Tyr Gln Glu Ala Leu Arg Ser Leu Cys Gln Lys Arg Asp Gly 130 135 140 Pro Arg Ala Thr Met Lys Ile Met Asn Tyr Asp Glu Phe Gln His Cys 145 150 155 160 Trp Ser Lys Phe Val Tyr Ser Gln Arg Glu Leu Phe Glu Pro Trp Asn 165 170 175 Asn Leu Pro Lys Tyr Tyr Ile Leu Leu His Ile Met Leu Gly Glu Ile 180 185 190 Leu Arg His Ser Met Asp Pro Pro Thr Phe Thr Phe Asn Phe Asn Asn 195 200 205 Glu Pro Trp Val Arg Gly Arg His Glu Thr Tyr Leu Cys Tyr Glu Val 210 215 220 Glu Arg Met His Asn Asp Thr Trp Val Leu Leu Asn Gln Arg Arg Gly 225 230 235 240 Phe Leu Cys Asn Gln Ala Pro His Lys His Gly Phe Leu Glu Gly Arg 245 250 255 His Ala Glu Leu Cys Phe Leu Asp Val Ile Pro Phe Trp Lys Leu Asp 260 265 270 Leu Asp Gln Asp Tyr Arg Val Thr Cys Phe Thr Ser Trp Ser Pro Cys 275 280 285 Phe Ser Cys Ala Gln Glu Met Ala Lys Phe Ile Ser Lys Asn Lys His 290 295 300 Val Ser Leu Cys Ile Phe Thr Ala Arg Ile Tyr Asp Asp Gln Gly Arg 305 310 315 320 Cys Gln Glu Gly Leu Arg Thr Leu Ala Glu Ala Gly Ala Lys Ile Ser 325 330 335 Ile Met Thr Tyr Ser Glu Phe Lys His Cys Trp Asp Thr Phe Val Asp 340 345 350 His Gln Gly Cys Pro Phe Gln Pro Trp Asp Gly Leu Asp Glu His Ser 355 360 365 Gln Asp Leu Ser Gly Arg Leu Arg Ala Ile Leu Gln Asn Gln Glu Asn 370 375 380 <210> 59 <211> 186 <212> PRT <213> Artificial <220> <223> hAPOBEC3G catalytic domain <400> 59 Pro Pro Thr Phe Thr Phe Asn Phe Asn Asn Glu Pro Trp Val Arg Gly 1 5 10 15 Arg His Glu Thr Tyr Leu Cys Tyr Glu Val Glu Arg Met His Asn Asp 20 25 30 Thr Trp Val Leu Leu Asn Gln Arg Arg Gly Phe Leu Cys Asn Gln Ala 35 40 45 Pro His Lys His Gly Phe Leu Glu Gly Arg His Ala Glu Leu Cys Phe 50 55 60 Leu Asp Val Ile Pro Phe Trp Lys Leu Asp Leu Asp Gln Asp Tyr Arg 65 70 75 80 Val Thr Cys Phe Thr Ser Trp Ser Pro Cys Phe Ser Cys Ala Gln Glu 85 90 95 Met Ala Lys Phe Ile Ser Lys Asn Lys His Val Ser Leu Cys Ile Phe 100 105 110 Thr Ala Arg Ile Tyr Asp Asp Gln Gly Arg Cys Gln Glu Gly Leu Arg 115 120 125 Thr Leu Ala Glu Ala Gly Ala Lys Ile Ser Ile Met Thr Tyr Ser Glu 130 135 140 Phe Lys His Cys Trp Asp Thr Phe Val Asp His Gln Gly Cys Pro Phe 145 150 155 160 Gln Pro Trp Asp Gly Leu Asp Glu His Ser Gln Asp Leu Ser Gly Arg 165 170 175 Leu Arg Ala Ile Leu Gln Asn Gln Glu Asn 180 185 <210> 60 <211> 200 <212> PRT <213> Homo sapiens <400> 60 Met Ala Leu Leu Thr Ala Glu Thr Phe Arg Leu Gln Phe Asn Asn Lys 1 5 10 15 Arg Arg Leu Arg Arg Pro Tyr Tyr Pro Arg Lys Ala Leu Leu Cys Tyr 20 25 30 Gln Leu Thr Pro Gln Asn Gly Ser Thr Pro Thr Arg Gly Tyr Phe Glu 35 40 45 Asn Lys Lys Lys Cys His Ala Glu Ile Cys Phe Ile Asn Glu Ile Lys 50 55 60 Ser Met Gly Leu Asp Glu Thr Gln Cys Tyr Gln Val Thr Cys Tyr Leu 65 70 75 80 Thr Trp Ser Pro Cys Ser Ser Cys Ala Trp Glu Leu Val Asp Phe Ile 85 90 95 Lys Ala His Asp His Leu Asn Leu Gly Ile Phe Ala Ser Arg Leu Tyr 100 105 110 Tyr His Trp Cys Lys Pro Gln Gln Lys Gly Leu Arg Leu Leu Cys Gly 115 120 125 Ser Gln Val Pro Val Glu Val Met Gly Phe Pro Lys Phe Ala Asp Cys 130 135 140 Trp Glu Asn Phe Val Asp His Glu Lys Pro Leu Ser Phe Asn Pro Tyr 145 150 155 160 Lys Met Leu Glu Glu Leu Asp Lys Asn Ser Arg Ala Ile Lys Arg Arg 165 170 175 Leu Glu Arg Ile Lys Ile Pro Gly Val Arg Ala Gln Gly Arg Tyr Met 180 185 190 Asp Ile Leu Cys Asp Ala Glu Val 195 200 <210> 61 <211> 373 <212> PRT <213> Homo sapiens <400> 61 Met Lys Pro His Phe Arg Asn Thr Val Glu Arg Met Tyr Arg Asp Thr 1 5 10 15 Phe Ser Tyr Asn Phe Tyr Asn Arg Pro Ile Leu Ser Arg Arg Asn Thr 20 25 30 Val Trp Leu Cys Tyr Glu Val Lys Thr Lys Gly Pro Ser Arg Pro Arg 35 40 45 Leu Asp Ala Lys Ile Phe Arg Gly Gln Val Tyr Ser Gln Pro Glu His 50 55 60 His Ala Glu Met Cys Phe Leu Ser Trp Phe Cys Gly Asn Gln Leu Pro 65 70 75 80 Ala Tyr Lys Cys Phe Gln Ile Thr Trp Phe Val Ser Trp Thr Pro Cys 85 90 95 Pro Asp Cys Val Ala Lys Leu Ala Glu Phe Leu Ala Glu His Pro Asn 100 105 110 Val Thr Leu Thr Ile Ser Ala Ala Arg Leu Tyr Tyr Tyr Trp Glu Arg 115 120 125 Asp Tyr Arg Arg Ala Leu Cys Arg Leu Ser Gln Ala Gly Ala Arg Val 130 135 140 Lys Ile Met Asp Asp Glu Glu Phe Ala Tyr Cys Trp Glu Asn Phe Val 145 150 155 160 Tyr Ser Glu Gly Gln Pro Phe Met Pro Trp Tyr Lys Phe Asp Asp Asn 165 170 175 Tyr Ala Phe Leu His Arg Thr Leu Lys Glu Ile Leu Arg Asn Pro Met 180 185 190 Glu Ala Met Tyr Pro His Ile Phe Tyr Phe His Phe Lys Asn Leu Arg 195 200 205 Lys Ala Tyr Gly Arg Asn Glu Ser Trp Leu Cys Phe Thr Met Glu Val 210 215 220 Val Lys His His Ser Pro Val Ser Trp Lys Arg Gly Val Phe Arg Asn 225 230 235 240 Gln Val Asp Pro Glu Thr His Cys His Ala Glu Arg Cys Phe Leu Ser 245 250 255 Trp Phe Cys Asp Asp Ile Leu Ser Pro Asn Thr Asn Tyr Glu Val Thr 260 265 270 Trp Tyr Thr Ser Trp Ser Pro Cys Pro Glu Cys Ala Gly Glu Val Ala 275 280 285 Glu Phe Leu Ala Arg His Ser Asn Val Asn Leu Thr Ile Phe Thr Ala 290 295 300 Arg Leu Tyr Tyr Phe Trp Asp Thr Asp Tyr Gln Glu Gly Leu Arg Ser 305 310 315 320 Leu Ser Gln Glu Gly Ala Ser Val Glu Ile Met Gly Tyr Lys Asp Phe 325 330 335 Lys Tyr Cys Trp Glu Asn Phe Val Tyr Asn Asp Asp Glu Pro Phe Lys 340 345 350 Pro Trp Lys Gly Leu Lys Tyr Asn Phe Leu Phe Leu Asp Ser Lys Leu 355 360 365 Gln Glu Ile Leu Glu 370 <210> 62 <211> 189 <212> PRT <213> Artificial <220> <223> hAPOBEC3F catalytic domain <400> 62 Lys Glu Ile Leu Arg Asn Pro Met Glu Ala Met Tyr Pro His Ile Phe 1 5 10 15 Tyr Phe His Phe Lys Asn Leu Arg Lys Ala Tyr Gly Arg Asn Glu Ser 20 25 30 Trp Leu Cys Phe Thr Met Glu Val Val Lys His His Ser Pro Val Ser 35 40 45 Trp Lys Arg Gly Val Phe Arg Asn Gln Val Asp Pro Glu Thr His Cys 50 55 60 His Ala Glu Arg Cys Phe Leu Ser Trp Phe Cys Asp Asp Ile Leu Ser 65 70 75 80 Pro Asn Thr Asn Tyr Glu Val Thr Trp Tyr Thr Ser Trp Ser Pro Cys 85 90 95 Pro Glu Cys Ala Gly Glu Val Ala Glu Phe Leu Ala Arg His Ser Asn 100 105 110 Val Asn Leu Thr Ile Phe Thr Ala Arg Leu Tyr Tyr Phe Trp Asp Thr 115 120 125 Asp Tyr Gln Glu Gly Leu Arg Ser Leu Ser Gln Glu Gly Ala Ser Val 130 135 140 Glu Ile Met Gly Tyr Lys Asp Phe Lys Tyr Cys Trp Glu Asn Phe Val 145 150 155 160 Tyr Asn Asp Asp Glu Pro Phe Lys Pro Trp Lys Gly Leu Lys Tyr Asn 165 170 175 Phe Leu Phe Leu Asp Ser Lys Leu Gln Glu Ile Leu Glu 180 185 <210> 63 <211> 1053 <212> PRT <213> Staphylococcus aureus <400> 63 Met Lys Arg Asn Tyr Ile Leu Gly Leu Asp Ile Gly Ile Thr Ser Val 1 5 10 15 Gly Tyr Gly Ile Ile Asp Tyr Glu Thr Arg Asp Val Ile Asp Ala Gly 20 25 30 Val Arg Leu Phe Lys Glu Ala Asn Val Glu Asn Asn Glu Gly Arg Arg 35 40 45 Ser Lys Arg Gly Ala Arg Arg Leu Lys Arg Arg Arg Arg His Arg Ile 50 55 60 Gln Arg Val Lys Lys Leu Leu Phe Asp Tyr Asn Leu Leu Thr Asp His 65 70 75 80 Ser Glu Leu Ser Gly Ile Asn Pro Tyr Glu Ala Arg Val Lys Gly Leu 85 90 95 Ser Gln Lys Leu Ser Glu Glu Glu Phe Ser Ala Ala Leu Leu His Leu 100 105 110 Ala Lys Arg Arg Gly Val His Asn Val Asn Glu Val Glu Glu Asp Thr 115 120 125 Gly Asn Glu Leu Ser Thr Lys Glu Gln Ile Ser Arg Asn Ser Lys Ala 130 135 140 Leu Glu Glu Lys Tyr Val Ala Glu Leu Gln Leu Glu Arg Leu Lys Lys 145 150 155 160 Asp Gly Glu Val Arg Gly Ser Ile Asn Arg Phe Lys Thr Ser Asp Tyr 165 170 175 Val Lys Glu Ala Lys Gln Leu Leu Lys Val Gln Lys Ala Tyr His Gln 180 185 190 Leu Asp Gln Ser Phe Ile Asp Thr Tyr Ile Asp Leu Leu Glu Thr Arg 195 200 205 Arg Thr Tyr Tyr Glu Gly Pro Gly Glu Gly Ser Pro Phe Gly Trp Lys 210 215 220 Asp Ile Lys Glu Trp Tyr Glu Met Leu Met Gly His Cys Thr Tyr Phe 225 230 235 240 Pro Glu Glu Leu Arg Ser Val Lys Tyr Ala Tyr Asn Ala Asp Leu Tyr 245 250 255 Asn Ala Leu Asn Asp Leu Asn Asn Leu Val Ile Thr Arg Asp Glu Asn 260 265 270 Glu Lys Leu Glu Tyr Tyr Glu Lys Phe Gln Ile Ile Glu Asn Val Phe 275 280 285 Lys Gln Lys Lys Lys Pro Thr Leu Lys Gln Ile Ala Lys Glu Ile Leu 290 295 300 Val Asn Glu Glu Asp Ile Lys Gly Tyr Arg Val Thr Ser Thr Gly Lys 305 310 315 320 Pro Glu Phe Thr Asn Leu Lys Val Tyr His Asp Ile Lys Asp Ile Thr 325 330 335 Ala Arg Lys Glu Ile Ile Glu Asn Ala Glu Leu Leu Asp Gln Ile Ala 340 345 350 Lys Ile Leu Thr Ile Tyr Gln Ser Ser Glu Asp Ile Gln Glu Glu Leu 355 360 365 Thr Asn Leu Asn Ser Glu Leu Thr Gln Glu Glu Ile Glu Gln Ile Ser 370 375 380 Asn Leu Lys Gly Tyr Thr Gly Thr His Asn Leu Ser Leu Lys Ala Ile 385 390 395 400 Asn Leu Ile Leu Asp Glu Leu Trp His Thr Asn Asp Asn Gln Ile Ala 405 410 415 Ile Phe Asn Arg Leu Lys Leu Val Pro Lys Lys Val Asp Leu Ser Gln 420 425 430 Gln Lys Glu Ile Pro Thr Thr Leu Val Asp Asp Phe Ile Leu Ser Pro 435 440 445 Val Val Lys Arg Ser Phe Ile Gln Ser Ile Lys Val Ile Asn Ala Ile 450 455 460 Ile Lys Lys Tyr Gly Leu Pro Asn Asp Ile Ile Ile Glu Leu Ala Arg 465 470 475 480 Glu Lys Asn Ser Lys Asp Ala Gln Lys Met Ile Asn Glu Met Gln Lys 485 490 495 Arg Asn Arg Gln Thr Asn Glu Arg Ile Glu Glu Ile Ile Arg Thr Thr 500 505 510 Gly Lys Glu Asn Ala Lys Tyr Leu Ile Glu Lys Ile Lys Leu His Asp 515 520 525 Met Gln Glu Gly Lys Cys Leu Tyr Ser Leu Glu Ala Ile Pro Leu Glu 530 535 540 Asp Leu Leu Asn Asn Pro Phe Asn Tyr Glu Val Asp His Ile Ile Pro 545 550 555 560 Arg Ser Val Ser Phe Asp Asn Ser Phe Asn Asn Lys Val Leu Val Lys 565 570 575 Gln Glu Glu Asn Ser Lys Lys Gly Asn Arg Thr Pro Phe Gln Tyr Leu 580 585 590 Ser Ser Ser Asp Ser Lys Ile Ser Tyr Glu Thr Phe Lys Lys His Ile 595 600 605 Leu Asn Leu Ala Lys Gly Lys Gly Arg Is Thr Lys Glu 610 615 620 Tyr Leu Leu Glu Glu Arg Asp With Asn Arg Phe Serving Val Gln Lys Asp 625 630 635 640 Phe Ile Asn Arg Asn Leu Val Asp Thr Arg Tyr Ala Thr Arg Gly Leu 645,650,655 Met Asn Leu Leu Arg Ser Tyr Phe Arg Val Asn Asn Leu Asp Val Lys 660,665,670 Val Lys Ser Ile Asn Gly Gly Phe Thr Ser Phe Leu Arg Arg Lys Trp 675,680,685 Lys Phe Lys Lys Glu Arg Asn Lys Gly Tyr Lys His Ala Glu Asp 690,695,700 Only Leu Ile On Asn Only Asp Phe Ile Phe Lys Glu Trp Lys Lys 705 710 715 720 Leu Asp Lys Ala Lys Lys Val Met Glu Asn Gln Met Phe Glu Glu Lys 725 730 735 Gln Ala Glu Ser Met Pro Glue Ile Glu Thr Glu Gln Glu Tyr Lys Glu 740,745,750 Ile Phe Ile Thr Pro His Gln Ile Lys His Ile Lys Asp Phe Lys Asp 755 760 765 Tyr Lys Tyr Ser His Arg Val Asp Lys Lys Pro Asn Arg Glu Leu Ile 770 775 780 Asn Asp Thr Leu Tyr Ser Thr Arg Lys Asp Asp Lys Gly Asn Thr Leu 785 790 795 800 Ile Val Asn Asn Leu Asn Gly Leu Tyr Asp Lys Asp Asn Asp Lys Leu 805 810 815 Lys Lys Leu Ile Asn Lys Ser Pro Glu Lys Leu Leu Met Tyr His His 820 825 830 Asp Pro Gln Thr Tyr Gln Lys Leu Lys Leu Ile Met Glu Gln Tyr Gly 835 840 845 Asp Glu Lys Asn Pro Leu Tyr Lys Tyr Tyr Glu Glu Thr Gly Asn Tyr 850 855 860 Leu Thr Lys Tyr Ser Lys Lys Asp Asn Gly Pro Val Ile Lys Lys Ile 865 870 875 880 Lys Tyr Tyr Gly Asn Lys Leu Asn Ala His Leu Asp Ile Thr Asp Asp 885 890 895 Tyr Pro Asn Ser Arg Asn Lys Val Val Lys Leu Ser Leu Lys Pro Tyr 900 905 910 Arg Phe Asp Val Tyr Leu Asp Asn Gly Val Tyr Lys Phe Val Thr Val 915 920 925 Lys Asn Leu Asp Val Ile Lys Lys Glu Asn Tyr Tyr Glu Val Asn Ser 930 935 940 Lys Cys Tyr Glu Glu Ala Lys Lys Leu Lys Lys Ile Ser Asn Gln Ala 945 950 955 960 Glu Phe Ile Ala Ser Phe Tyr Asn Asn Asp Leu Ile Lys Ile Asn Gly 965 970 975 Glu Leu Tyr Arg Val Ile Gly Val Asn Asn Asp Leu Leu Asn Arg Ile 980 985 990 Glu Val Asn Met Ile Asp Ile Thr Tyr Arg Glu Tyr Leu Glu Asn Met 995 1000 1005 Asn Asp Lys Arg Pro Pro Arg Ile Ile Lys Thr Ile Ala Ser Lys 1010 1015 1020 Thr Gln Ser Ile Lys Lys Tyr Ser Thr Asp Ile Leu Gly Asn Leu 1025 1030 1035 Tyr Glu Val Lys Ser Lys Lys His Pro Gln Ile Ile Lys Lys Gly 1040 1045 1050 <210> 64 <211> 984 <212> PRT <213> Campylobacter jejuni <400> 64 Met Ala Arg And Leu Ala Phe Asp And Gly And Ser Ser And Gly Trp 1 5 10 15 Ala Phe Ser Glu Asn Asp Glu Leu Lys Asp Cys Gly Val Arg Ile Phe 20 25 30 Thr Lys Val Glu Asn Pro Lys Thr Gly Glu Ser Leu Ala Leu Pro Arg 35 40 45 Arg Leu Ala Arg Ser Ala Arg Lys Arg Leu Ala Arg Arg Lys Ala Arg 50 55 60 Leu Asn His Leu Lys His Leu Ile Ala Asn Glu Phe Lys Leu Asn Tyr 65 70 75 80 Glu Asp Tyr Gln Ser Phe Asp Glu Ser Leu Ala Lys Ala Tyr Lys Gly 85 90 95 Ser Leu Ile Ser Pro Tyr Glu Leu Arg Phe Arg Ala Leu Asn Glu Leu 100 105 110 Lys Gln Asp Phe Ala Arg Val Ile Leu His Ile Ala Lys Arg 115 120 125 Arg Gly Tyr Asp Asp Ile Lys Asn Ser Asp Asp Lys Glu Lys Gly Ala 130 135 140 With Lys Only Only Only With Lys On Gln Asn Glu Glu Lys With Only On Tyr Gln 145 150 155 160 Ser Val Gly Glu Tyr Leu Tyr Lys Glu Tyr Phe Gln Lys Phe Lys Glu 165 170 175 Asn Ser Lys Glu Phe Thr Asn Val Arg Asn Lys Glu Ser Tyr Glu 180 185 190 Arg Cys contains Gln Ser with Lys Asp and Glu with Lys 195 200 205 Lys Lys Gln Arg Glu Phe Gly Phe Ser Phe Ser Lys Phe Glu Glu 210 215 220 Glu Val Leu Ser Val Ala Phe Tyr Lys Arg Ala Leu Lys Asp Phe Ser 225 230 235 240 His Leu Val Gly Asn Cys Ser Phe Phe Thr Asp Glu Lys Arg Ala Pro 245 250 255 Lys Asn Ser Pro Leu Ala Phe Met Phe Val Ala Leu Thr Arg Ile Ile 260 265 270 Asn Leu Asn Asn Leu Lys Asn Thr Glu Gly And Leu Tyr Thr Lys 275 280 285 Asp Asp Leu Asn Ala Leu Asn Glu Val Leu Lys Asn Gly Thr Leu 290,295,300 Thr Tyr Lys Gln Thr Lys Lys Leu Gly Leu Ser Asp Asp Tyr Glu 305 310 315 320 Phe Lys Gly Glu Lys Gly Thr Tyr Phe Ile Glu Phe Lys Lys Tyr Lys 325 330 335 Glu Phe Ile Lys Ala Leu Gly Glu His Asn Leu Ser Gln Asp Asp Leu 340 345 350 Asn Glu With Lys Asp With Thr Leu With Lys Asp Glu With Lys Leu 355 360 365 Lys Lys Ala Leu Ala Lys Tyr Asp Leu Asn Gln Asn Gln Ile Asp Ser 370 375 380 Leu Ser Lys Leu Glu Phe Lys Asp His Leu Asn Ile Ser Phe Lys Ala 385 390 395 400 Leu Lys Leu Val Thr Pro Leu Met Leu Glu Gly Lys Lys Tyr Asp Glu 405 410 415 Only Cys Isn't Glued To Asn To Lys And Only Ile Isn't Glued To Asp Lys Lys 420 425 430 Asp Phe Leu Pro Ala Phe Asn Glu Thr Tyr Tyr Lys Asp Glu Val Thr 435 440 445 Asn Pro Asn Val Val Leu Arg Ala Ile Lys Glu Tyr Arg Lys Val Val Leu Donkey 450 455 460 Ala Leu Lys Lys Tyr Gly Lys Val His Lys Ile Asn Ile Glu Leu 465 470 475 480 Ala Arg Glu Val Gly Lys Asn His Ser Gln Arg Ala Lys Ile Glu Lys 485 490 495 Glu Gln Asn Glu Asn Tyr Lys Ala Lys Lys Asp Ala Glu Leu Glu Cys 500 505 510 Glu Lys Leu Gly Leu Lys Ile Asn Ser Lys Asn Ile Leu Lys Leu Arg 515 520 525 Leu Phe Lys Glu Gln Lys Glu Phe Cys Ala Tyr Ser Gly Glu Lys Ile 530 535 540 Lys Ile Ser Asp Leu Gln Asp Glu Lys Met Leu Glu Ile Asp His Ile 545 550 555 560 Tyr Pro Tyr Ser Arg Ser Phe Asp Asp Ser Tyr Met Asn Lys Val Leu 565 570 575 Val Phe Thr Lys Gln Asn Gln Glu Lys Leu Asn Gln Thr Pro Phe Glu 580 585 590 Ala Phe Gly Asn Asp Ser Ala Lys Trp Gln Lys Ile Glu Val Leu Ala 595 600 605 Lys Asn Leu Pro Thr Lys Lys Gln Lys Arg Ile Leu Asp Lys Asn Tyr 610 615 620 Lys Asp Lys Glu Gln Lys Asn Phe Lys Asp Arg Asn Leu Asn Asp Thr 625 630 635 640 Arg Tyr Ile Ala Arg Leu Val Leu Asn Tyr Thr Lys Asp Tyr Leu Asp 645,650,655 Phe Leu Pro Leu Ser Asp Asp Glu Asn Thr Lys Leu Asn Asp Thr Gln 660,665,670 Lys Gly Ser Lys Val His Val Glu Ala Lys Ser Gly Met Leu Thr Ser 675,680,685 Ala Leu Arg His Thr Trp Gly Phe Ser Ala Lys Asp Arg Asn Asn His 690,695,700 Leu His His Only Asp Only Val Only Only Tyr Only Asn Asn Ser 705 710 715 720 Ile Val Lys Ala Phe Ser Asp Phe Lys Lys Glu Gln Glu Ser Asn Ser 725 730 735 Glu Leu Tyr Ala Lys Lys Ser Glu Leu Asp Tyr Lys Asn Lys 740,745,750 Arg Lys Phe Glu Pro Phe Ser Gly Phe Arg Gln Lys Val Leu Asp 755,760,765 Lys Ile Asp Glu Ile Phe Val Ser Lys Pro Glu Arg Lys Lys Pro Ser 770,775,780 Gly Ala Leu His Glu Glu Thr Phe Arg Lys Glu Glu Glu Phe Tyr Gln 785,790,795,800 Ser Tyr Gly Gly Lys Glu Gly Val Leu Lys Ala Leu Glu Leu Gly Lys 805 810 815 Ile Arg Lys Val Asn Gly Lys Ile Val Lys Asn Gly Asp Met Phe Arg 820 825 830 Val Asp Ile Phe Lys His Lys Lys Thr Asn Lys Phe Tyr Ala Val Pro 835 840 845 Ile Tr Thr Met Asp Phe Ala Leu Lys Val Leu Pro Asn Lys Ala Val 850 855 860 Only Arg Ser Lys Lys Gly Glu Ile Lys Asp Trp Ile Leu Met Asp Glu 865 870 875 880 Asn Tyr Glu Phe Cys Phe Ser Leu Tyr Lys Asp Ser Leu Ile Leu Ile 885,890,895 Gln Thr Lys Asp Met Gln Glu Pro Glu Phe Val Tyr Asn Ala Phe 900 905 910 His Asp Asn Lys Phe 915,920,925 Glu Thr Serves Lys Asn With Gln Lys And Has Phe Lys Asn On Glu 930,935,940 Lys Glu Val Ile Ala Lys Ser Ile Gly Ile Gln Asn Leu Lys Val Phe 945 950 955 960 Glu Lys Tyr Ile Val Ser Ala Leu Gly Glu Val Thr Lys Ala Glu Phe 965 970 975 Arg Gln Arg Glu Asp Phe Lys Lys 980 <210> 65 <211> 1037 <212> PRT <213> Parvibaculum lavamentivorans (Parvibaculum lavamentivorans) <400> 65 Met Glu Arg Ile Phe Gly Phe Asp Ile Gly Thr Thr Ser Ile Gly Phe 1 5 10 15 Ser Val Ile Asp Tyr Ser Ser Thr Gln Ser Ala Gly Asn Ile Gln Arg 20 25 30 Leu Gly Val Arg Ile Phe Pro Glu Ala Arg Asp Pro Asp Gly Thr Pro 35 40 45 Leu Asn Gln Gln Arg Arg Gln Lys Arg Met Met Arg Arg Gln Leu Arg 50 55 60 Arg Arg Arg Ile Arg Arg Lys Ala Leu Asn Glu Thr Leu His Glu Ala 65 70 75 80 Gly Phe Leu Pro Ala Tyr Gly Ser Ala Asp Trp Pro Val Val Met Ala 85 90 95 Asp Glu Pro Tyr Glu Leu Arg Arg Arg Gly Leu Glu Glu Gly Leu Ser 100 105 110 Ala Tyr Glu Phe Gly Arg Ala Ile Tyr His Leu Ala Gln His Arg His 115 120 125 Phe Lys Gly Arg Glu Leu Glu Glu Ser Asp Thr Pro Asp Pro Asp Val 130 135 140 Asp Asp Glu Lys Glu Ala Ala Asn Glu Arg Ala Ala Thr Leu Lys Ala 145 150 155 160 Leu Lys Asn Glu Gln Thr Thr Leu Gly Ala Trp Leu Ala Arg Arg Pro 165 170 175 Pro Ser Asp Arg Lys Arg Gly Ile His Ala His Arg Asn Val Val Ala 180 185 190 Glu Glu Phe Glu Arg Leu Trp Glu Val Gln Ser Lys Phe His Pro Ala 195 200 205 Leu Lys Ser Glu Glu Met Arg Ala Arg Ile Ser Asp Thr Ile Phe Ala 210 215 220 Gln Arg Pro Val Phe Trp Arg Lys Asn Thr Leu Gly Glu Cys Arg Phe 225 230 235 240 Met Pro Gly Glu Pro Leu Cys Pro Lys Gly Ser Trp Leu Ser Gln Gln 245 250 255 Arg Arg Met Leu Glu Lys Leu Asn Asn Leu Ala Ile Ala Gly Gly Asn 260 265 270 Ala Arg Pro Leu Asp Ala Glu Glu Arg Asp Ala Ile Leu Ser Lys Leu 275 280 285 Gln Gln Gln Ala Ser Met Ser Trp Pro Gly Val Arg Ser Ala Leu Lys 290 295 300 Ala Leu Tyr Lys Gln Arg Gly Glu Pro Gly Ala Glu Lys Ser Leu Lys 305 310 315 320 Phe Asn Leu Glu Leu Gly Gly Glu Ser Lys Leu Leu Gly Asn Ala Leu 325 330 335 Glu Ala Lys Leu Ala Asp Met Phe Gly Pro Asp Trp Pro Ala His Pro 340 345 350 Arg Lys Gln Glu Ile Arg His Ala Val His Glu Arg Leu Trp Ala Ala 355 360 365 Asp Tyr Gly Glu Thr Pro Asp Lys Lys Arg Val Ile Ile Leu Ser Glu 370 375 380 Lys Asp Arg Lys Ala His Arg Glu Ala Ala Ala Asn Ser Phe Val Ala 385 390 395 400 Asp Phe Gly Ile Thr Gly Glu Gln Ala Ala Gln Leu Gln Ala Leu Lys 405 410 415 Leu Pro Thr Gly Trp Glu Pro Tyr Ser Ile Pro Ala Leu Asn Leu Phe 420 425 430 Leu Ala Glu Leu Glu Lys Gly Glu Arg Phe Gly Ala Leu Val Asn Gly 435 440 445 Pro Asp Trp Glu Gly Trp Arg Arg Thr Asn Phe Pro His Arg Asn Gln 450 455 460 Pro Thr Gly Glu Ile Leu Asp Lys Leu Pro Ser Pro Ala Ser Lys Glu 465 470 475 480 Glu Arg Glu Arg Ile Ser Gln Leu Arg Asn Pro Thr Val Val Arg Thr 485 490 495 Gln Asn Glu Leu Arg Lys Val Val Asn Asn Leu Ile Gly Leu Tyr Gly 500 505 510 Lys Pro Asp Arg Ile Arg Ile Glu Val Gly Arg Asp Val Gly Lys Ser 515 520 525 Lys Arg Glu Arg Glu Glu Ile Gln Ser Gly Ile Arg Arg Asn Glu Lys 530 535 540 Gln Arg Lys Lys Ala Thr Glu Asp Leu Ile Lys Asn Gly Ile Ala Asn 545 550 555 560 Pro Ser Arg Asp Asp Val Glu Lys Trp Ile Leu Trp Lys Glu Gly Gln 565 570 575 Glu Arg Cys Pro Tyr Thr Gly Asp Gln Ile Gly Phe Asn Ala Leu Phe 580 585 590 Arg Glu Gly Arg Tyr Glu Val Glu His Ile Trp Pro Arg Ser Arg Ser 595 600 605 Phe Asp Asn Ser Pro Arg Asn Lys Thr Leu Cys Arg Lys Asp Val Asn 610 615 620 Ile Glu Lys Gly Asn Arg Met Pro Phe Glu Ala Phe Gly His Asp Glu 625 630 635 640 Asp Arg Trp Ser Ala Ile Gln Ile Arg Leu Gln Gly Met Val Ser Ala 645 650 655 Lys Gly Gly Thr Gly Met Ser Pro Gly Lys Val Lys Arg Phe Leu Ala 660 665 670 Lys Thr Met Pro Glu Asp Phe Ala Ala Arg Gln Leu Asn Asp Thr Arg 675 680 685 Tyr Ala Ala Lys Gln Ile Leu Ala Gln Leu Lys Arg Leu Trp Pro Asp 690 695 700 Met Gly Pro Glu Ala Pro Val Lys Val Glu Ala Val Thr Gly Gln Val 705 710 715 720 Thr Ala Gln Leu Arg Lys Leu Trp Thr Leu Asn Asn Ile Leu Ala Asp 725 730 735 Asp Gly Glu Lys Thr Arg Ala Asp His Arg His His Ala Ile Asp Ala 740 745 750 Leu Thr Val Ala Cys Thr His Pro Gly Met Thr Asn Lys Leu Ser Arg 755 760 765 Tyr Trp Gln Leu Arg Asp Asp Pro Arg Ala Glu Lys Pro Ala Leu Thr 770 775 780 Pro Pro Trp Asp Thr Ile Arg Ala Asp Ala Glu Lys Ala Val Ser Glu 785 790 795 800 Ile Val Val Ser His Arg Val Arg Lys Lys Val Ser Gly Pro Leu His 805 810 815 Lys Glu Thr Thr Tyr Gly Asp Thr Gly Thr Asp Ile Lys Thr Lys Ser 820 825 830 Gly Thr Tyr Arg Gln Phe Val Thr Arg Lys Lys Ile Glu Ser Leu Ser 835 840 845 Lys Gly Glu Leu Asp Glu Ile Arg Asp Pro Arg Ile Lys Glu Ile Val 850 855 860 Ala Ala His Val Ala Gly Arg Gly Gly Asp Pro Lys Lys Ala Phe Pro 865 870 875 880 Pro Tyr Pro Cys Val Ser Pro Gly Gly Pro Glu Ile Arg Lys Val Arg 885 890 895 Leu Thr Ser Lys Gln Gln Leu Asn Leu Met Ala Gln Thr Gly Asn Gly 900 905 910 Tyr Ala Asp Leu Gly Ser Asn His His Ile Ala Ile Tyr Arg Leu Pro 915 920 925 Asp Gly Lys Ala Asp Phe Glu Ile Val Ser Leu Phe Asp Ala Ser Arg 930 935 940 Arg Leu Ala Gln Arg Asn Pro Ile Val Gln Arg Thr Arg Ala Asp Gly 945 950 955 960 Ala Ser Phe Val Met Ser Leu Ala Ala Gly Glu Ala Ile Met Ile Pro 965 970 975 Glu Gly Ser Lys Lys Gly Ile Trp Ile Val Gln Gly Val Trp Ala Ser 980 985 990 Gly Gln Val Val Leu Glu Arg Asp Thr Asp Ala Asp His Ser Thr Thr 995 1000 1005 Thr Arg Pro Met Pro Asn Pro Ile Leu Lys Asp Asp Ala Lys Lys 1010 1015 1020 Val Ser Ile Asp Pro Ile Gly Arg Val Arg Pro Ser Asn Asp 1025 1030 1035 <210> 66 <211> 1082 <212> PRT <213> Neisseria cinerea <400> 66 Met Ala Ala Phe Lys Pro Asn Pro Met Asn Tyr Ile Leu Gly Leu Asp 1 5 10 15 Ile Gly Ile Ala Ser Val Gly Trp Ala Ile Val Glu Ile Asp Glu Glu 20 25 30 Glu Asn Pro Ile Arg Leu Ile Asp Leu Gly Val Arg Val Phe Glu Arg 35 40 45 Ala Glu Val Pro Lys Thr Gly Asp Ser Leu Ala Ala Ala Arg Arg Leu 50 55 60 Ala Arg Ser Val Arg Arg Leu Thr Arg Arg Arg Ala His Arg Leu Leu 65 70 75 80 Arg Ala Arg Arg Leu Leu Lys Arg Glu Gly Val Leu Gln Ala Ala Asp 85 90 95 Phe Asp Glu Asn Gly Leu Ile Lys Ser Leu Pro Asn Thr Pro Trp Gln 100 105 110 Leu Arg Ala Ala Ala Leu Asp Arg Lys Leu Thr Pro Leu Glu Trp Ser 115 120 125 Ala Val Leu Leu His Leu Ile Lys His Arg Gly Tyr Leu Ser Gln Arg 130 135 140 Lys Asn Glu Gly Glu Thr Ala Asp Lys Glu Leu Gly Ala Leu Leu Lys 145 150 155 160 Gly Val Ala Asp Asn Thr His Ala Leu Gln Thr Gly Asp Phe Arg Thr 165 170 175 Pro Ala Glu Leu Ala Leu Asn Lys Phe Glu Lys Glu Ser Gly His Ile 180 185 190 Arg Asn Gln Arg Gly Asp Tyr Ser His Thr Phe Asn Arg Lys Asp Leu 195 200 205 Gln Ala Glu Leu Asn Leu Leu Phe Glu Lys Gln Lys Glu Phe Gly Asn 210 215 220 Pro His Val Ser Asp Gly Leu Lys Glu Gly Ile Glu Thr Leu Leu Met 225 230 235 240 Thr Gln Arg Pro Ala Leu Ser Gly Asp Ala Val Gln Lys Met Leu Gly 245 250 255 His Cys Thr Phe Glu Pro Thr Glu Pro Lys Ala Ala Lys Asn Thr Tyr 260 265 270 Thr Ala Glu Arg Phe Val Trp Leu Thr Lys Leu Asn Asn Leu Arg Ile 275 280 285 Leu Glu Gln Gly Ser Glu Arg Pro Leu Thr Asp Thr Glu Arg Ala Thr 290 295 300 Leu Met Asp Glu Pro Tyr Arg Lys Ser Lys Leu Thr Tyr Ala Gln Ala 305 310 315 320 Arg Lys Leu Leu Asp Leu Asp Asp Thr Ala Phe Phe Lys Gly Leu Arg 325 330 335 Tyr Gly Lys Asp Asn Ala Glu Ala Ser Thr Leu Met Glu Met Lys Ala 340 345 350 Tyr His Ala Ile Ser Arg Ala Leu Glu Lys Glu Gly Leu Lys Asp Lys 355 360 365 Lys Ser Pro Leu Asn Leu Ser Pro Glu Leu Gln Asp Glu Ile Gly Thr 370 375 380 Ala Phe Ser Leu Phe Lys Thr Asp Glu Asp Ile Thr Gly Arg Leu Lys 385 390 395 400 Asp Arg Val Gln Pro Glu Ile Leu Glu Ala Leu Leu Lys His Ile Ser 405 410 415 Phe Asp Lys Phe Val Gln Ile Ser Leu Lys Ala Leu Arg Arg Ile Val 420 425 430 Pro Leu Met Glu Gln Gly Asn Arg Tyr Asp Glu Ala Cys Thr Glu Ile 435 440 445 Tyr Gly Asp His Tyr Gly Lys Lys Asn Thr Glu Glu Lys Ile Tyr Leu 450 455 460 Pro Pro Ile Pro Ala Asp Glu Ile Arg Asn Pro Val Val Leu Arg Ala 465 470 475 480 Leu Ser Gln Ala Arg Lys Val Ile Asn Gly Val Val Arg Arg Tyr Gly 485 490 495 Ser Pro Ala Arg Ile His Ile Glu Thr Ala Arg Glu Val Gly Lys Ser 500 505 510 Phe Lys Asp Arg Lys Glu Ile Glu Lys Arg Gln Glu Glu Asn Arg Lys 515 520 525 Asp Arg Glu Lys Ser Ala Ala Lys Phe Arg Glu Tyr Phe Pro Asn Phe 530 535 540 Val Gly Glu Pro Lys Ser Lys Asp Ile Leu Lys Leu Arg Leu Tyr Glu 545 550 555 560 Gln Gln His Gly Lys Cys Leu Tyr Ser Gly Lys Glu Ile Asn Leu Gly 565 570 575 Arg Leu Asn Glu Lys Gly Tyr Val Glu Ile Asp His Ala Leu Pro Phe 580 585 590 Ser Arg Thr Trp Asp Asp Ser Phe Asn Asn Lys Val Leu Ala Leu Gly 595 600 605 Ser Glu Asn Gln Asn Lys Gly Asn Gln Thr Pro Tyr Glu Tyr Phe Asn 610 615 620 Gly Lys Asp Asn Ser Arg Glu Trp Gln Glu Phe Lys Ala Arg Val Glu 625 630 635 640 Thr Ser Arg Phe Pro Arg Ser Lys Lys Gln Arg Ile Leu Leu Gln Lys 645 650 655 Phe Asp Glu Asp Gly Phe Lys Glu Arg Asn Leu Asn Asp Thr Arg Tyr 660 665 670 Ile Asn Arg Phe Leu Cys Gln Phe Val Ala Asp His Met Leu Leu Thr 675 680 685 Gly Lys Gly Lys Arg Arg Val Phe Ala Ser Asn Gly Gln Ile Thr Asn 690 695 700 Leu Leu Arg Gly Phe Trp Gly Leu Arg Lys Val Arg Ala Glu Asn Asp 705 710 715 720 Arg His His Ala Leu Asp Ala Val Val Val Ala Cys Ser Thr Ile Ala 725 730 735 Met Gln Gln Lys Ile Thr Arg Phe Val Arg Tyr Lys Glu Met Asn Ala 740 745 750 Phe Asp Gly Lys Thr Ile Asp Lys Glu Thr Gly Glu Val Leu His Gln 755 760 765 Lys Ala His Phe Pro Gln Pro Trp Glu Phe Phe Ala Gln Glu Val Met 770 775 780 Ile Arg Val Phe Gly Lys Pro Asp Gly Lys Pro Glu Phe Glu Glu Ala 785 790 795 800 Asp Thr Pro Glu Lys Leu Arg Thr Leu Leu Ala Glu Lys Leu Ser Ser 805 810 815 Arg Pro Glu Ala Val His Lys Tyr Val Thr Pro Leu Phe Ile Ser Arg 820 825 830 Ala Pro Asn Arg Lys Met Ser Gly Gln Gly His Met Glu Thr Val Lys 835 840 845 Ser Ala Lys Arg Leu Asp Glu Gly Ile Ser Val Leu Arg Val Pro Leu 850 855 860 Thr Gln Leu Lys Leu Lys Asp Leu Glu Lys Met Val Asn Arg Glu Arg 865 870 875 880 Glu Pro Lys Leu Tyr Glu Ala Leu Lys Ala Arg Leu Glu Ala His Lys 885 890 895 Asp Asp Pro Ala Lys Ala Phe Ala Glu Pro Phe Tyr Lys Tyr Asp Lys 900 905 910 Ala Gly Asn Arg Thr Gln Gln Val Lys Ala Val Arg Val Glu Gln Val 915 920 925 Gln Lys Thr Gly Val Trp Val His Asn His Asn Gly Ile Ala Asp Asn 930 935 940 Ala Thr Ile Val Arg Val Asp Val Phe Glu Lys Gly Gly Lys Tyr Tyr 945 950 955 960 Leu Val Pro Ile Tyr Ser Trp Gln Val Ala Lys Gly Ile Leu Pro Asp 965 970 975 Arg Ala Val Val Gln Gly Lys Asp Glu Glu Asp Trp Thr Val Met Asp 980 985 990 Asp Ser Phe Glu Phe Lys Phe Val Leu Tyr Ala Asn Asp Leu Ile Lys 995 1000 1005 Leu Thr Ala Lys Lys Asn Glu Phe Leu Gly Tyr Phe Val Ser Leu 1010 1015 1020 Asn Arg Ala Thr Gly Ala Ile Asp Ile Arg Thr His Asp Thr Asp 1025 1030 1035 Ser Thr Lys Gly Lys Asn Gly Ile Phe Gln Ser Val Gly Val Lys 1040 1045 1050 Thr Ala Leu Ser Phe Gln Lys Tyr Gln Ile Asp Glu Leu Gly Lys 1055 1060 1065 Glu Ile Arg Pro Cys Arg Leu Lys Lys Arg Pro Pro Val Arg 1070 1075 1080 <210> 67 <211> 1003 <212> PRT <213> Campylobacter lari <400> 67 Met Arg Ile Leu Gly Phe Asp Ile Gly Ile Asn Ser Ile Gly Trp Ala 1 5 10 15 Phe Val Glu Asn Asp Glu Leu Lys Asp Cys Gly Val Arg Ile Phe Thr 20 25 30 Lys Ala Glu Asn Pro Lys Asn Lys Glu Ser Leu Ala Leu Pro Arg Arg 35 40 45 Asn Ala Arg Ser Ser Arg Arg Arg Leu Lys Arg Arg Lys Ala Arg Leu 50 55 60 Ile Ala Ile Lys Arg Ile Leu Ala Lys Glu Leu Lys Leu Asn Tyr Lys 65 70 75 80 Asp Tyr Val Ala Ala Asp Gly Glu Leu Pro Lys Ala Tyr Glu Gly Ser 85 90 95 Leu Ala Ser Val Tyr Glu Leu Arg Tyr Lys Ala Leu Thr Gln Asn Leu 100 105 110 Glu Thr Lys Asp Leu Ala Arg Val Ile Leu His Ile Ala Lys His Arg 115 120 125 Gly Tyr Met Asn Lys Asn Glu Lys Serve Asn Asp Ala Lys Gly 130 135 140 Lys Ile Leo Ser Only Lys Asn Asn Only On Lys Only Glu Asn Tyr 145 150 155 160 Gln Ser Val Gly Glu Tyr Phe Tyr Lys Glu Phe Phe Gln Lys Tyr Lys 165 170 175 Lys Asn Thr Lys Asn Phe Ile Lys Ile Arg Asn Thr Lys Asp Asn Tyr 180 185 190 Asn Asn Cys Will Be Asp Lew Glu Lys Glu Lew Lys Leu Ile 195 200 205 Leu Glu Lys Gln Lys Glu Phe Gly Tyr Asn Tyr Ser Glu Asp Phe Ile 210 215 220 Asn Glue With Lys Val Ala Phe Phe Gln Arg Pro Leu Lys Asp Phe 225 230 235 240 Ser Leu Val Gly Ala Cys Thr Phe Phe Glu Glu Glu Lys Arg Ala 245 250 255 Cys Lys Asn Ser Tyr Ser Ala Trp Glu Phe Val Ala Leu Thr Lys Ile 260 265 270 Ile Asn Glu Ile Lys Ser Leu Glu Lys Ile Ser Gly Glu Ile Val Pro 275 280 285 Thr Gln Thr Ile Asn Glu Val Leu Asn Leu Ile Leu Asp Lys Gly Ser 290 295 300 Ile Thr Tyr Lys Lys Phe Arg Ser Cys Ile Asn Leu His Glu Ser Ile 305 310 315 320 Ser Phe Lys Ser Leu Lys Tyr Asp Lys Glu Asn Ala Glu Asn Ala Lys 325 330 335 Leu Ile Asp Phe Arg Lys Leu Val Glu Phe Lys Lys Ala Leu Gly Val 340 345 350 His Ser Leu Ser Arg Gln Glu Leu Asp Gln Ile Ser Thr His Ile Thr 355 360 365 Leu Ile Lys Asp Asn Val Lys Leu Lys Thr Val Leu Glu Lys Tyr Asn 370 375 380 Leu Ser Asn Glu Gln Ile Asn Asn Leu Leu Glu Ile Glu Phe Asn Asp 385 390 395 400 Tyr Ile Asn Leu Ser Phe Lys Ala Leu Gly Met Ile Leu Pro Leu Met 405 410 415 Arg Glu Gly Lys Arg Tyr Asp Glu Ala Cys Glu Ile Ala Asn Leu Lys 420 425 430 Pro Lys Thr Val Asp Glu Lys Lys Asp Phe Leu Pro Ala Phe Cys Asp 435 440 445 Ser Ile Phe Ala His Glu Leu Ser Asn Pro Val Val Asn Arg Ala Ile 450 455 460 Ser Glu Tyr Arg Lys Val Leu Asn Ala Leu Leu Lys Tyr Gly Lys 465 470 475 480 Will His Lys And His Leu Glu Leu Wing Asp Will Gly Leu Ser Lys 485,490,495 Lys Ala Arg Glu Lys Ile Glu Lys Glu Gln Lys Glu Asn Gln Ala Val 500 505 510 Asn Ala Trp Ala Leu Lys Glu Cys Glu Asn Ile Gly Leu Lys Ala Ser 515,520,525 Only Lys Asn Ile Leu Lys Leu Lys Trp Lys Glu Gln Lys Glu Ile 530 535 540 Cys Ile Ser Gly Asn Lys Ile Ser Ile Glu His Lys Asp Glu 545 550 555 560 Lys Ala Leu Glu Val Asp His Ile Tyr Pro Tyr Ser Arg Ser Phe Asp 565,570,575 Asp Ser Phe Ile Asn Lys Val Leu Val Phe Thr Lys Glu Asn Gln Glu 580,585,590 Lys Leu Asn Lys Thr Pro Phe Glu Ala Phe Gly Lys Asn Ile Glu Lys 595 600 605 Trp Ser Lys Ile Gln Thr Leu Ala Gln Asn Leu Pro Tyr Lys Lys Lys 610 615 620 Asn Lys Ile Leu Asp Glu Asn Phe Lys Asp Lys Gln Gln Glu Asp Phe 625 630 635 640 Ile Ser Arg Asn Leu Asn Asp Thr Arg Tyr Ile Ala Thr Leu Ile Ala 645 650 655 Lys Tyr Thr Lys Glu Tyr Leu Asn Phe Leu Leu Leu Ser Glu Asn Glu 660 665 670 Asn Ala Asn Leu Lys Ser Gly Glu Lys Gly Ser Lys Ile His Val Gln 675 680 685 Thr Ile Ser Gly Met Leu Thr Ser Val Leu Arg His Thr Trp Gly Phe 690 695 700 Asp Lys Lys Asp Arg Asn Asn His Leu His His Ala Leu Asp Ala Ile 705 710 715 720 Ile Val Ala Tyr Ser Thr Asn Ser Ile Ile Lys Ala Phe Ser Asp Phe 725 730 735 Arg Lys Asn Gln Glu Leu Leu Lys Ala Arg Phe Tyr Ala Lys Glu Leu 740,745,750 Thr Ser Asp Asn Tyr Lys His Gln Val Lys Phe Phe Glu Pro Phe Lys 755,760,765 Ser Phe Arg Glu Lys Ile Leu Ser Lys Ile Asp Glu Ile Phe Val Ser 770,775,780 Lys Pro Pro Arg Lys Arg Ala Arg Arg Ala Leu His Lys Asp Thr Phe 785,790,795,800 His Ser Glu Asn Lys Ile Ile Asp Lys Cys Ser Tyr Asn Ser Glu 805 810 815 Gly Leu Gln Ile Ala Leu Serves as Cys Gly Arg Val Arg Lys Ile Gly Thr 820 825 830 Lys Tyr Val Glu Asn Asp Thr Ile Val Arg Val Asp Ile Phe Lys Lys 835 840 845 Gln Asn Lys Phe Tyr Ala Ile Pro Ile Tyr Ala Met Asp Phe Ala Leu 850 855 860 Gly Ile Leu Pro Asn Lys Ile Val Ile Thr Gly Lys Asp Lys Asn Asn 865 870 875 880 Asn Pro Lys Gln Trp Gln Thr Ile Asp Glu Ser Tyr Glu Phe Cys Phe 885,890,895 Ser Tyr Lys Asn Asp Leu Ile Leu Gln Lys Lys Asn Met Gln 900 905 910 Glu Pro Glu Phe Ala Tyr Tyr Asn Asp Phe Ser Ile Ser Thr Ser Ser 915 920 925 Ile Cys Val Glu Lys His Asp Asn Lys Phe Glu Asn Leu Thr Ser Asn 930 935 940 Gln Lys Leu Leu Phe Ser Asn Ala Lys Glu Gly Ser Val Lys Val Glu 945 950 955 960 Ser Leu Gly Ile Gln Asn Leu Lys Val Phe Glu Lys Tyr Ile Ile Thr 965 970 975 Pro Leu Gly Asp Lys Ile Lys Ala Asp Phe Gln Pro Arg Glu Asn Ile 980 985 990 Ser Leu Lys Thr Ser Lys Lys Tyr Gly Leu Arg 995 1000
Claims
1. A fusion protein comprising a Cas9-like nickase nCas9 linked to an engineered variant human apolipoprotein B mRNA editing enzyme catalytic subunit 3A (hAPOBEC3A) deaminase via an optional intervening linker, wherein the amino acid sequence of the engineered variant hAPOBEC3A deaminase is the amino acid sequence shown in SEQ ID NO: 57 and comprises one of the following mutations of SEQ ID NO: 57: N57A, N57Q, N57S, N57G, N57A / K60A, N57A / K60D, N57A / K60Q, N57A / K60 S, N57A / Y130F, N57L / K60D, N57L / K60N, N57Q / K60D, N57Q / K60N, N57Q / Y 130F, N57S / K60D, N57S / K60N, N57A / K60N, N57G / I96T, N57G / I96V, N57G / W98Y, N57G / L135E, N57G / Q141E, N57G / G170E, N57G / E38K, N57G / A71V.
2. Use of the fusion protein according to claim 1 in the preparation of a medicament for treating a subject having a beta-thalassemia mutation HBB-28, A>G by the following method, the method comprising delivering a therapeutically effective amount of the fusion protein according to claim 1.
3. The use according to claim 2, wherein the fusion protein comprises a Cas9 that generates ssDNA nicks or is inactive in catalysis.
4. The method according to claim 2 or 3, wherein the fusion protein is delivered in the form of RNP, mRNA or plasmid.
5. The use according to claim 2 or 3, wherein the method comprises delivering the fusion protein ex vivo to a population of cells comprising CD34+ hematopoietic stem cells and / or progenitor cells collected from the subject under conditions sufficient to deaminize the mutant, and returning the cells to the subject.
6. An in vitro method for deaminating selected cytidines in a nucleic acid, the method comprising contacting the nucleic acid with the fusion protein according to claim 1.
7. A composition comprising the purified fusion protein according to claim 1.
8. The composition according to claim 7, comprising one or more ribonucleoprotein (RNP) complexes.
9. A nucleic acid encoding the fusion protein according to claim 1.
10. A vector comprising the nucleic acid according to claim 9.
11. An isolated host cell comprising the nucleic acid according to claim 9, wherein the host cell is a yeast cell, an E. coli cell, an insect cell or a hematopoietic stem cell.
